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General Abstract 
 
Towards the development of a drug delivery vehicle for the nasal delivery of insulin, N-trimethyl 
chitosan has been co-formulated with poly(ethylene glycol) and glycerophosphate into a 
thermosensitive hydrogel structure, the sol-to-gel transition properties of which occur at 
physiologically relevant temperatures over optimally brief timescales.  In vitro experiments 
mimicking those of the nasal environment have indicated the dual capability of the formulation to 
affect the opening of tight junctions and to release its therapeutic content in a controlled manner, 
while spectroscopic and analytical investigations have indicated the structural integrity of the 
incorporated insulin. The in vivo potential of this in situ thermogelling nasal formulation to act as a 
once-a-day dosage form for the intranasal delivery of insulin has been demonstrated in the diabetic 
rat model.
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Hydrogels in Mucosal Delivery 
 
 
 Abstract  
 
The concept of mucoadhesion and the molecular design requirements for the synthesis of 
mucoadhesive agents are both well understood, and as a result hydrogel formulations that 
may be applied to mucosal surfaces are readily accessible. Nano-sized hydrogel systems that 
make use of biological recognition or targeting motifs, by reacting to disease-specific 
environmental triggers and/or chemical signals to effect drug release, are now emerging as 
components of a new generation of therapeutics that promise improved residence time, faster 
response to stimuli and trigger release.  
 
 
1.1. Mucosal membranes 
 
Mucosal surfaces are rendered attractive for the delivery of drugs by their: high degree of 
vascularisation; generally thin layers of epithelial cells; large surface-area to volume ratios; and, with 
exception of the oral route, avoidance of the first-pass metabolic effect. The impetus for research in 
transmucosal drug delivery is provided not only by the ongoing drive to improve the delivery of 
existing low-molecular-weight drugs and therapeutic macromolecules [1] but also by the need to 
evolve effective dosage forms for the delivery of emerging biologics. It has been suggested that the 
efficacy of many therapeutic agents may improve if they were to be delivered specifically through 
the nasal [2-5], pulmonary [6], buccal [7-10], oral [11-13], vaginal [14-16], rectal [17] or ocular [18, 
19] routes.  
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Human mucosal membranes have a collective surface area of 400 m2 [20], and consist of a thin layer 
of differentiated epithelial cells that are attached basally to the basement membrane, which 
separates the epithelium from the underlying connective tissues (lamina propia). The basal cells of 
this basement membrane are packed closely, forming a robust barrier to most microorganisms but 
also to drug absorption.  Some of the physiological features characterising each mucosal membrane 
are presented in Table 1. 
Chapter One 
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Mucosal 
membrane 
Cells of the epithelia Surface 
area 
Mucus Additional barriers Temp/
C 
pH Refs 
 
Ocular Corneal epithelium: 5-6 layers of cells; basally 
columnar with tight junctions (TJ) that differentiate as 
flattened polygonal cells with microvilli.  Cornea 
impermeable to molecules > 5kDa. Conjunctival 
epithelium: 5-7 cell layers, including goblet cells.  TJ at 
surface. Conjunctiva is permeable to macromolecules 
<20 kDa. 
 
16.3 cm2 Daily production, 2-3 µL; mucus 
turnover, 15-20 h; pre-corneal film 
(10 µL)   made up of a superficial 
lipid layer, a central aqueous layer 
and an inner mucus layer (3-10 µm 
thick).  
Nasolacrymal drainage consisting of 
secretory, distributive and collection 
parts. Tears spread over surface; 
collection at canaliculi, lacrimal sac, 
nasolacrimal sac and nasolacrimal duct 
leading to nasal passage. Basal tear flow, 
ca. 1.2 µL/min; turnover rate 16%/min, 
but highly sensitive to reflex stimulation 
(up to 100-fold). 
34 7.4 with 
diurnal 
changes from 
acid to 
alkaline  
[21-
23] 
Buccal Buccal: non-keratinised stratified squamous 
epithelium, 40-50 cell layers thick (500-600 µm); blood 
flow 2.4 mL/min.  Sublingual: non-keratinised stratified 
squamous epithelium, ca. 100-200 µm thick; blood 
flow 0.97 mL/min. 
 
Oral cavity 
100 cm2. 
Buccal  50.2 
cm2 
Thickness, 40-300 µm. Mucus 
turnover 12-24 h. Saliva film, ca. 70 
µm thick;  resting flow rate, 1-2 
mL/min. 
Permeability barrier due to membrane-
coating granules (MCGs), which cause 
membrane thickening, cell adhesion, 
deposition of a coating on the cells, and 
cell desquamation. Salivary scavenging 
and accidental swallowing. Residence time 
< 5-10 min. 
32-37 Average: oral, 
6.78, buccal, 
6.28 
[7, 8, 
24-
26] 
Gastro-
intestinal 
Single layer of columnar epithelium, with TJ. Also 
present: Peyer’s patches of the gut-associated 
lymphoid tissue (GALT); these are lined with specialised 
epithelium-containing microfold (M) cells. 
Small 
intestine 
200m2 
Two forms in stomach: insoluble 
mucus protects underlying cells 
from gastric acid; soluble mucus is 
derived from degraded insoluble 
mucus. 
High rate of mucus turnover, broad transit 
time, enzymatic degradation, hepatic first-
pass metabolism, luminal degradation. 
Oesop
hageal 
approx
. 37 
Stomach, 
pH1-3; 
intestine 
pH6-7 
 
[11, 
23, 
27-
29] 
Nasal Anterior: stratified, keratinised, non-ciliated squamous 
cells with sebaceous glands. Olfactory (found 
posteriorly): ciliated olfactory nerve cells, 200-400 
mm2. Respiratory: ciliated and non-ciliated columnar 
cells; goblet and basal cells. 
Polar drugs <1 kDa are transportable via a paracellular 
mechanism. 
150 cm2 Resting-state daily production at 
75-150 mL; mucus blanket, ca.5µm 
thick. 
Mucociliary clearance (MCC) ca. 4-
6mm/min; dimensions of nasal cavity 
restrict volume to 100-500 µL; enzymatic 
activity. 
 
32-35 6 [3, 5, 
30-
33] 
Pulmonary Bronchi: ciliated and goblet cells.  Bronchioles: ciliated 
cuboidal cells; fewer goblet cells.  Alveolar: simple 
squamous; no mucus; 0.1-0.5 µm thick. 
100 m2 Tracheobronchial (TB) region: 
thickness, 0.5-5 µm; absent in 
alveoli. 
TB region with MCC removing particles 
and dissolved drugs entrapped in mucus 
within a few hours. 
 
Trache
a 34-37  
Exhaled 
breathing 
condensate 
7.6 
 
[34-
38] 
Vaginal Non-cornified, stratified squamous epithelial cells 
(thickness, 200-300µm); no goblet cells. 
Extends from uterus to the external genitalia. 
6-10 cm 
(length) × 
ca. 2 cm 
(width). 
Holds 2-3g 
of liquid 
Flow rate of vaginal fluid, 2-3 
g/day. 
Rapid removal from the site of application 
via discharge; poor spreading of 
administered mucoadhesive.  
37.2 3.5-4.5 
influenced by 
age, 
menstrual 
cycle, 
infections, 
and sexual 
arousal 
[23, 
39-
41] 
Table 1. Physiological features of mucosal membranes and the associated barriers to penetration.  
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1.2. Absorption pathways 
 Types 
 
The effective permeability of each type of mucosa varies according to the type of cells that make up 
the epithelia that cover the basement membrane. Four possible mechanisms of transport across 
mucosal membranes have been identified: simple diffusion (transcellular and paracellular); carrier-
mediated diffusion; active transport; and, pinocytosis or endocytosis [27]. It is generally accepted 
that the key mode for the transference of materials is passive transport, but this is highly influenced 
by the nature of the permeant molecule (structure, conformation, charge, lipophilicity).  
Transcellular transport is primarily favoured by small lipophilic molecules, which diffuse through the 
cells from one side of the barrier to the other. Large, charged, hydrophilic molecules may be 
transported paracellularly. In general, however, the free flow of material from the apical lumen into 
the blood stream is inhibited by tight junctions and the associated junctional complexes that are 
localised between neighbouring cells [27]. Consequently, drug-delivery strategies often attempt the 
transient disruption of the conformation of protein subunits to allow the passage of drug molecules 
that would otherwise be excluded. 
 
 Barriers to penetration across the mucosa 
 
The common feature shared by mucosal membranes (basement membrane, the associated layers of 
epithelial cells and the overlying layer of proteinaceous-glycol mucus) is the barrier to absorption. 
Additional specialised protective and/or locomotive mechanisms may also operate within each 
mucosal membrane, Table 1.  
 
 
Chapter One 
 
6 
 
 Mucus 
 
Apart from water (>95 %), mucus is comprised mainly of exceptionally high molecular weight 
glycoproteins (mucins; 2-14 x 106 g/mol) and relatively small proportions (ca. 1%) of proteins, 
mucopolysaccharides, lipids and inorganic salts [42, 43]; it is the glycoproteins that impart gel-like 
characteristics to mucus [42]. The mucus glycoproteins may be considered as graft polymers 
consisting of a protein backbone and pendent oligosaccharide chains comprised of sugar residues 
(fucose, galactose, N-acetylgalactosamine, N-glucosamine and sialic acid) [7]. Owing to their low pKa, 
sialic acid and sulphated sugar moieties exist in their fully ionised forms at physiologically relevant 
acidic conditions, rendering mucus negatively charged [44]. The barrier properties stem from the 
dense glycoproteinic component, which bestows mucus with significant water-holding capacity and 
imparts resistance to proteolysis [7]. 
Mucus is secreted by goblet cells, which are glandular epithelial cells found in all mucosal linings that 
may become exposed to the external environment. The mucins are stored in goblet cells and in 
submucosal cells where their negative charges are counterbalanced by the reservoir of calcium ions 
to form a tightly packed structure. Secretion into the lumen is accompanied by an outflux of calcium 
ions and the consequent establishment of intramolecular electrostatic repulsions, which stem from 
the negative charges that are localised along the mucin molecule. This results in a ca. 400-fold 
expansion in molecular size, but chain entanglement and the structuring of water around individual 
mucin molecules give mucus its characteristic viscoelastic gel structure [43].  
In addition to acting as a barrier to solids, mucus functions as a permeable lubricating gel that 
maintains hydration and allows the transfer of gases and nutrients to the underlying epithelium [43]. 
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1.3. Mucoadhesion 
 Interactions facilitating mucoadhesion 
 
Bioadhesion is the adherence of a material to a biological surface for an extended period of time; if 
that biological surface is covered with a layer of mucus, the term mucoadhesion is used [8, 42, 43, 
45]. Owing to the complexity of the process of mucoadhesion, several theories have been proposed 
to explain its mechanism [7, 8, 43, 45], Fig. 1. These are the: electronic theory, in which adhesion is 
explained in terms of the electron transfer across the double layer of electrical charge that is 
established at the interface of two interacting surfaces; adsorption theory, where the dominant 
surface forces are considered to be van der Waals’ interactions and hydrogen-bond formation; 
wetting theory, which assumes the interaction between mucus and mucoadhesive to be a process 
that is dominated by structural similarity, complementary degrees of cross-linking and the surface-
tension-lowering action of surfactants; diffusion theory, in which chain interpenetration is regarded 
as the main mode of interaction between the mucus and the mucoadhesive; and, fracture theory, 
where the adhesive force between the interacting systems is treated as consequential to the 
interfacial energy [43, 45]. 
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Figure 1. Schematic representation of mucoadhesive behaviour: A) electronic theory; B) 
adsorption theory; C) wettability theory; D) diffusion theory, and E) fracture theory. 
 
 Factors influencing mucoadhesion 
 
Mucoadhesive drug delivery has been rationalised in terms of its potential to maintain a therapeutic 
molecule at a mucosal site for a prolonged period of time [23]. The concept of mucoadhesive 
interactions evolved from a suggestion by Ishida et al. [46] who demonstrated the increased 
bioavailability of a polymer-containing intranasal peptide preparation, and further suggested that 
polymers may be used in formulations of anti-inflammatory treatments for ankle injuries or in those 
for the local treatment of cervical cancer. Since mucoadhesive behaviour is determined both by the 
nature of the bioadhesive polymer and by that of the aqueous medium that is necessary for its 
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delivery to the mucosal surface, each mucoadhesive delivery system needs to be optimised 
according to the local environment of the target mucoadhesive surface [45].  
 Functional group contribution 
 
It is well accepted that polymers possessing functional groups that can interact with the glycoprotein 
component of mucins via hydrogen bonding (carboxyl, -COOH; hydroxyl, -OH; amino, -NH2; and 
sulphate groups, -SO4H) are effective mucoadhesive agents [43]. The archetypal mucoadhesive agent 
is poly(acrylic acid), which interacts with mucus not only by the hydrogen bonds that form between 
the carboxyl groups of poly(acrylic acid) and the sialic residues of mucin glycoproteins but also by 
favourable interactions of the van der Waals’ type. Hagesaether and Sande [47] examined  the 
significance of hydrogen bonding within the process of mucoadhesion by considering the effects of 
added urea, a well-accepted hydrogen bonding disruptor, to mucus/pectin mixtures: the 
considerable reduction in mucoadhesive behaviour was manifested as a decrease in cohesion and as 
loss of rheological synergy [47]. Additional to the instantaneous contributions of ionic, hydrogen and 
van der Waals’ interactions, the time-dependent establishment of covalent bonding may also play a 
role in certain, appropriately functionalised mucoadhesive systems [48]. It has been suggested [48], 
within the context of mucus-turnover time, that such covalent interactions strengthen 
mucoadhesion.  
 Degree of hydration 
 
It has been observed that mucoadhesion is facilitated by the ready hydration and the capacity of a 
mucoadhesive polymer to swell rapidly but to a limited extent [8, 49]. The wetting theory accounts 
for this observation in terms of the associated water-induced decrease in the barrier to rotation of 
the hydrated polymer and the consequent enhancement of its capacity for chain interpenetration 
with the underlying mucus [23, 43]. The significance of rapid but limited swelling is exemplified by 
the work of Xiang et al. [50] who investigated the relationship between hydrophilic-lipophilic 
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balance (HLB) and mucoadhesive behaviour for a range of poly (acrylic acid-polyethylene glycol 
monomethylether monomethacrylate dimethylaminoethyl acrylate). It was observed that above a 
certain degree of hydration, polymers adopt an extended chain structure that inhibits their 
propensity to establish mucoadhesive interactions by limiting their capacity to become entangled 
with mucus glycoproteins. 
 Structural characteristics of polymeric mucoadhesives 
 
The mucoadhesive behaviour of a polymeric mucoadhesive is sensitive to its average molecular 
weight, chain length, conformation and degree of crosslinking [49, 51]. Whilst a high average 
molecular weight is a general prerequisite to macromolecular-chain entanglement, excessively 
crosslinked polymer structures may become too rigid to form such interactions with mucus 
molecules [43]. The optimal range of average molecular weight is unique to each polymeric 
mucoadhesive: poly (acrylic acid) is reported to be optimally mucoadhesive at ca. 750 kDa, whilst 
poly(ethylene oxide) interacts most efficiently with mucus if it has an average molecular weight  of 
ca. 4,000 kDa. In the case of chitosan, there is a direct relationship between average molecular 
weight and mucoadhesive efficiency [52], whilst dextran exhibits the same bioadhesive strength at 
ca. 19,500 kDa as it does at 200 kDa (this has been explained in terms of the shielding of the 
potential bioadhesive sites of the higher molecular weight structure as a result of its coiled-helix 
conformation) [43]. 
 Charge and pH  
 
Although it is generally accepted that non-ionic polymers are not as mucoadhesive as ionisable 
structures, this needs to be considered within the context of the pH of the physiological 
environment within which the polymer must display its mucoadhesive behaviour. In view of the 
toxicity that is sometimes associated with polycationic structures, polyanions are considered as the 
bioadhesive materials of choice for all such applications [8, 43]. Studies on poly(acrylic acid)s have 
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shown that these materials, although optimally mucoadhesive in their fully protonated form, 
continue to exhibit mucoadhesive behaviour under all physiologically relevant pH environments [23, 
43]. 
 Polymer concentration 
 
The physical state of the delivery system, and consequently the concentration of the mucoadhesive 
polymer in the formulation, is of some significance [51], especially in semi-solid dosage forms [43]. 
Concentration at the site of action is also of significance, as is exemplified by the work of Madsen et 
al. [53] who reported that the optimal polyacrylic acid concentration for ocular preparations is in the 
range 0.05-0.2% w/v. Andrews et al. state that for a semi solid state, an optimum concentration 
exists for the polymer beyond which reduced adhesion occurs due to fewer polymer chains available 
to interpenetrate with mucus. In solid dosage forms an increase in polymer concentration can result 
in increased adhesive strength as is demonstrated by buccal tablets.[54] 
 Environmental factors 
 
The physiological environment (mucus thickness, pH, mucus turnover) are all factors influencing 
mucoadhesive behaviour [5], Table 2 [43, 45]. 
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Table 2. Environmental factors influencing mucoadhesive behaviour 
Factors Comments 
pH The extent of protonation is proportional to the electrical charges 
localised along the mucus backbone, which in turn impact upon 
the strength of the mucoadhesive interaction. 
 
Mucin turnover The residence time of a mucoadhesive drug delivery system may in 
some cases be limited by mucus turnover, which may in turn 
reflect circadian rhythms. 
 
Disease states Certain conditions (e.g. common cold, cystic fibrosis, gastric ulcers, 
ulcerative colitis, inflammation) alter the physicochemical 
properties of mucus. 
 
Mucus thickness and viscosity Thick layers favour polymer/mucus bond formation but greater 
thickness presents a more robust barrier to drug absorption. Low-
viscosity mucus is associated with weak mucoadhesive 
interactions; increased viscosity augments the barrier to drug 
diffusion. 
 
1.4. The assessment of mucoadhesive behaviour 
Since no standard test methods are recognised for the evaluation of mucoadhesion, researchers 
normally report the relative mucoadhesion efficiencies of materials in terms of a ranking order that 
is specific to the in vitro or in vivo method used for the determination. Although there are 
considerable variations within the relative mucoadhesive efficiencies reported by different research 
groups, the ranking positions of individual classes of mucoadhesive materials do not appear to be 
sensitive to the methodology adopted for the evaluation. 
 In vitro methods 
 
The most widely used method for the assessment of mucoadhesion involves the determination of 
the force, and the associated work of adhesion, that is required to detach a material from a 
biological substrate. In an early attempt to quantify mucoadhesion, Smart et al. [55] studied a range 
of polymers using an adaptation of the Wilhelmy plate technique, a technique that provides a 
measure of the work done on passing a plate coated with a mucoadhesive polymer through the 
mucus/air interface [56].  
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A readily accessible means for the evaluation of mucoadhesion is tensile testing. The use of dual 
tensiometers has been claimed to allow the modelling of the effects of the shear stresses that 
operate at the site of administration [57], while the use of texture analysers has allowed the study of 
the relationship between mucus/mucoadhesive contact time and force of adhesion [58]. 
Experiments in which a mucoadhesive is brought into contact with excised biological mucosa and the 
force of detachment is measured are now considered routine in the assessment of the 
mucoadhesive potential of a material [44, 50, 59]. 
The rheological profile of the polymer-mucin mixture is a powerful in vitro model of mucoadhesive 
behaviour [53]. The development of rheological synergism in such mixtures is a pre-requisite to 
mucoadhesive interaction [43]. The concept was pioneered by Hassan and Gallo [60] who studied 
the mucoadhesive capacity of a range of polymers by comparing the rheology of binary 
polymer/mucus mixtures with those of mono-component mucus and polymer systems. Work by 
Madsen et al. [53] has demonstrated the importance of polymer type and concentration in the 
development of synergistic effects with mucus. Further work by the same group established that the 
mucus mixtures of polymers capable of mucoadhesive behaviour exhibit rheological profiles that are 
characteristic of a weakly cross-linked gel network, and that gel strengthening is influenced by the 
acidity of the local biological environment [42]. Consequent to these findings, the rheological 
evaluation of mucus-mucoadhesive mixtures is considered integral to the study of such systems [61, 
62].  
Comparative studies of tensile mucoadhesive testing and shear rheological tests using three 
poly(acrylic acid)-based polymers and reconstituted mucus have shown that the two techniques give 
the same rank order of mucoadhesion, highlighting the complementarity of the two techniques in 
the evaluation of this property [63-65].  
The use of fluorescent probes has found some applications in the evaluation of ocular [43] and 
oesophageal [66] formulations. Infrared spectroscopy in attenuated total reflectance (ATR) mode 
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[67] has provided evidence in support of the theory of chain interpenetration at the poly(acrylic 
acid)/mucin interface. The same mucus/mucoadhesive system has been studied by Patel et al. [68] 
who have reported that combined data from infrared, 1H and 13C nuclear magnetic resonance 
(NMR), X-ray photoelectron spectroscopy (XPS) and differential scanning calorimetry (DSC) studies 
support the hypothesis that in such mixtures the mucus tends to encapsulate the mucoadhesive 
agent, and that there are fewer H-bonded interactions between the interacting materials than 
within the bulk of the pure mucoadhesive polymer. The same workers have provided spectroscopic 
evidence that the pH of the medium influences the structures of both the poly(acrylic acid) and the 
mucus, which, in turn, determine the nature and the extent of mucoadhesive interactions.  
 Following earlier atomic force microscopy (AFM) work by Sriamornsak et al. [69], Joergensen et al. 
[70] employed the techniques of AFM and surface plasmon resonance (SPR) to assess the 
mucoadhesive characteristics of pectins. Esposito et al. [71] and Lehr et al. [72], who investigated 
the relationship between surface energy and mucoadhesive behaviour, report a direct correlation 
with corresponding results from the tensile testing of adhesive strength. Since a correlation was 
unmasked between the fractional surface polarity of the substrate (pig small intestine mucus gel) 
and the mucoadhesive (polycarbophil), it has been concluded that the consideration of surface 
energy data needs to be integral to strategies for the development of improved mucoadhesive 
materials, not least because of their effect on the control of spreading processes [71, 72]. 
A method that monitors the zeta potential of the suspension formed when mucin powder is added 
to solutions of methylated N-aryl chitosan derivatives has been developed by Takeuchi et al. [73], 
who report that the change in the zeta potential of mucin particles correlates with increased 
interactions between the substrate and the mucoadhesive [74]. 
Using a polyether-modified poly(acrylic acid), Cleary et al. [75] combined data from AFM, 
tensiometric force measurements and advancing contact angle determinations to assess adhesion to 
mucin as a function of pH and ionic strength. The results again highlighted the relative significance of 
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the combined effects of hydrogen-bond formation, van der Waals’ interactions and electrostatic 
forces on the process of mucoadhesion [75].                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
 In vivo methods 
 
Some work has been done in the in vivo testing of mucoadhesive systems, with much of the effort 
focusing on  nasal and oral dosage forms [43].  
The non-invasive technique of choice for the evaluation of mucoadhesion involves the monitoring of 
gamma-emitting radiolabelled polymers via gamma scintigraphy, as is exemplified by human 
clearance studies of radiolabelled chitosan and starch microspheres, and chitosan solution [76]. It 
was reported that the chitosan solution had a clearance that was double that of the control; starch 
microspheres of more than triple and the chitosan microspheres were retained for  four times as 
long as the control. These results supported the hypothesis that chitosan delivery systems can 
reduce the rate of clearance from the nasal cavity and thereby increase the bioavailability of drugs 
incorporated into these systems [74]. The technique has also been employed by Richardson et al. 
[77] for the study of the distribution of technetium-labelled microspheres of a hyaluronic acid 
derivative (HYAFF) in the genital tract of sheep. 
The technique of magnetic resonance imaging has been employed by Albrecht et al. [78] to localise 
the point of release of thiolated polymers from dosage forms and to determine residence time in the 
intestinal mucosa of rats. 
Donovan et al. [79] has demonstrated a simple technique for monitoring nasal clearance. The 
method involved the timed collection of nasally instilled microspheres (non-absorbable 
FluoSpheres® of sulphated latex particles) via swabbing of the back of the oral cavity. 
Riley et al. [80] have employed the rat model to determine the in vivo gastrointestinal distribution 
profiles of three 14C -labelled poly(acrylic acid)s with differing degrees of crosslinking, and hence 
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different average molecular weights. These structural features were found to be of little influence to 
the overall gastrointestinal transit of the materials under consideration. Within the first hour from 
administration, a smaller proportion of the lower molecular weight polymer, as compared with the 
higher molecular weight materials, was seen to be retained in the stomach but after this time the 
observed profiles for all three polymers became essentially identical. After four hours, irrespective of 
the material utilised, the stomach was free of all polymer; at six hours from ingestion, all polymers 
were found to concentrate in the caecum with only small amounts of material present in the ileum 
or in the lower large intestine. No evidence for the systemic absorption of poly(acrylic acids) could 
be identified following the scintillation counting of NaOH-digested samples of liver, kidneys, blood, 
and urine. 
Roldo et al. [81] determined the in vivo (rat) gastrointestinal distribution profile of orally 
administered millimetre-sized particles, prepared from 14C-radiolabelled poly(acrylic acid) that had 
been crosslinked with 4-4’divinylazobenzene, Figure 2. The work has shown the capability of these 
particles to swell progressively along the gastrointestinal tract (GIT) and develop into colon-specific 
hydrogel coatings that exhibit prolonged residence and mucoadhesion specificity. Additionally, the 
efficacy of the selected material as a protective coating for the colonic mucosa has been tested in a 
hapten-reactivated in vivo model of inflammatory bowel disease. Seven days after reactivation of 
the condition, the myeloperoxidase activity of animals that had received doses of the selected 
azopolymer was determined to be at the same level as that of healthy animals or that of the 
negative control group, highlighting the therapeutic promise of this material. 
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Figure 2. GIT distribution profile of azocrosslinked polyacrylic acid (      stomach;       small intestine;       
caecum/colon;        total); radiolabelled polymer appeared in the faeces after 24 hours from oral 
administration (Based on data from Roldo et al. [81]) 
 
1.5. Formulation design 
 
The concept of mucoadhesive drug delivery systems was first conceived in 1980 as a means of 
overcoming physiological barriers in sustained and targeted drug delivery by placing the formulation 
in intimate contact with the absorption site [82]. The complexities for the design of an effective 
mucoadhesive formulation are highlighted by the multitude of performance demands that such a 
system must meet before it can be considered appropriate for clinical testing. A therapeutically 
relevant mucoadhesive must display [83]: 
 rapid but limited swelling, wetting and spreading on contact with aqueous media; 
 adhesiveness to the mucosal layer; 
 capacity to exhibit prolonged residence at the site of administration; 
 pKa values that are appropriate to the physiological environment of interest; 
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 viscoelastic behaviour; 
 controlled release of the loaded active;  
 biocompatibility; and, 
 efficient clearance from the site of administration and/or biodegradability to molecular 
entities that do not cause adverse effects. 
The search for mucoadhesive drug delivery systems that meet these demands has considered a 
range of systems, including patches, tablets, gels, pastes, inserts and nanoparticles [82]. 
 Hydrogels 
 
Ever since they were first introduced in the 1960s, hydrogels have continued to be investigated for a 
multitude of therapeutic applications  [84]. These cross-linked polymeric networks are capable of 
imbibing water and of acting as semi-solid dosage forms for drug delivery and as supporting 
materials that promote tissue regeneration. In their swollen state they share some of the physical 
properties that characterise biological tissues: soft consistency, which minimises their capacity to act 
as irritants; high affinity for water and biological fluids, which in addition to increasing 
biocompatibility inhibits the adsorption of proteins and cell, and hence reduces the likelihood of a 
negative immune response; and, they are deformable, which allows them to adapt to the shape  of 
the underlying mucosa of the target organ [85]. 
 Pharmaceutical considerations 
 
Hydrogels have been classified into entangled networks, covalently cross-linked networks, and 
networks formed by physical interactions [86] but very few systems conform with the pure definition 
of each class [87]. Consequently, attempts have been made to describe hydrogels in many ways. The  
nature of side groups (neutral or ionic) or mechanical and structural features can be used to 
differentiate types. The hydrogel can be described by its method of preparation (homo- or co-
polymer). The physical structure (amorphous, semi-crystalline, hydrogen-bonded, supermolecular, 
Chapter One 
 
19 
 
and hydrocolloidal) can be used to classify the systems. Also if appropriate hydrogelscan be defined 
by their responsiveness to physiological environmental stimuli (pH, temperature, ionic strength, 
electromagnetic radiation and redox potential) [88]. The reasons for the lack of a universally 
acceptable system for the classification of hydrogels are exemplified. In a review of chitosans, Dash 
et al.[89] describe the variety of hydrogel types that this naturally occurring polymer is capable of 
forming. Firstly, physical association networks which are maintained through non-covalent 
interactions. Ionic complexes are stabilised by electrostatic interaction between cationic and anionic 
species and analogous to ionic complexes are polyelectrolyte complexes maintained by stronger 
inter-ion interactions since they involve large charged molecules. Polymeric blends consist of 
physical admixtures and irreversible cross-linked networks formed through chemical cross-linking or 
by appropriately formulated interpenetrating networks. Lastly, stimuli sensitive thermo-reversible 
hydrogels are described which exhibit temperature-triggered sol-to-gel transitions. The application 
of oscillatory rheological  methods, has allowed Hunt et al. [90] to classify alginate structures as true 
gels (viscoelastic solids) or as concentrated polymer solutions (viscoelastic liquids), suggesting that 
rheology [91, 92] may be a readily accessible tool for the classification of such systems irrespective 
of the mechanism that governs their formation. 
The capability of a hydrogel to act as a drug delivery device is determined by the combined effects of 
the two parameters that define its swollen state, namely, polymer volume fraction, which measures 
the amount of fluid a hydrogel can absorb, and the average number of constitutional repeat units 
between each cross-linking point along the polymer backbone, which determines the structure of 
the network mesh and hence the average pore size, and impacts upon mechanical strength, 
degradability and the diffusivity of a loaded molecule [93]. Typically, biomedical hydrogels in their 
swollen state have pore sizes in the range 5 - 100 nm, which are considerably larger than that of the 
majority of small-molecule drugs and renders them inappropriate for the delivery of such agents 
[85]. The use of hydrogels is thus limited to applications demanding the sustained release of 
macromolecular drugs that are characterised by large hydrodynamic radii, such as peptides, proteins 
Chapter One 
 
20 
 
and oligonucleotides. Lü et al. [94] have reported the release of BSA, a protein with a hydrodynamic 
diameter of 7.2 nm, which is smaller than the average pore size of the oxidised 
carboxymethylcellulose/N-succinyl-chitosan carrier hydrogel: an initial Fickian diffusion of the 
incorporated BSA (which has been explained in terms of the progressive swelling of the hydrogel and 
the consequential increase in hydrodynamic radii) is reported to have been followed  by a stage of 
zero-order release that appeared to be governed by the degradation profile of the hydrogel.  
The mechanism for the release of a loaded drug from a hydrogel is influenced by chemical structure, 
mesh size and the swelling properties of the carrier system, Table 3. 
Table 3. Possible mechanisms for the release of a loaded drug from a hydrogel 
Drug release Mechanisms 
Diffusion controlled Drug diffusion is dependent upon hydrogel mesh sizes. Normally 
modelled using Fick’s law of diffusion. 
 
Swelling controlled Drug diffusion is faster than hydrogel swelling. Modelling involves 
moving boundary conditions where molecules are released at the 
interface between rubbery and glassy phases of swollen hydrogels. 
 
Chemically controlled Drug release is dependent upon chemical reactions occurring within 
the gel matrix, e.g. hydrolytic or enzymatic degradation of polymer 
chains. 
 
A range of hydrogels has been explored for the controlled delivery of many actives, ranging from 
small molecular weight drugs to nucleic acids, peptides and proteins [95-97]. Loading with low 
molecular weight drugs normally involves the placement of the fully formed gel into a medium that 
has been saturated with the therapeutic agent. Macromolecular therapeutics are normally 
incorporated into the polymer mix before the onset of gelation. In a typical example, Wu et al. [4] 
formulated a range of thermosensitive hydrogels for the release of insulin by mixing systematically 
varied proportions of the active with N-[(2-hydroxy-3-trimethylammonium) propyl] chitosan chloride 
(HTCC) and polyethylene glycol, before the addition of αβ-glycerophosphate, the gel-network 
facilitator, and heating to 37° C. The work has shown that the proportion of loaded insulin is limited 
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by its capacity to participate in hydrogen bond formation with PEG and/or HTCC, which strengthens 
the network and inhibits release [4]. 
Following in vivo administration both loading methods are characterised by a burst release stage, 
which precedes the onset of controlled-release behaviour – this has been explained in terms of the 
time lag for the equilibration of the concentration gradient between the hydrogel and the 
surrounding environment [27]. The normal formulation strategy for the minimisation of drug loss 
during the burst-release stage involves the linking of the active to the polymer via labile covalent 
bonds that are susceptible to degradation (enzymatic, redox, acid mediated) at the local biological 
environment [85].  This has been carried out with a number of small molecular weight drugs, such as 
paclitaxel, dexamethasone and fluvastatin [98-101]. The covalent conjugation has afforded drug 
release to be extended from weeks to months. The thermosensitive polyphosphazene-paclitaxel 
conjugate gel was reported to sustainably release paclitaxel for up to one month. A degradable 
lactide bond was used to conjugate dexamethasone to a photoreactive mono-acrylated polyethylene 
glycol (PEG) in order to facilitate osetogenic differentiation of human mesenchymal  stem cells [100]. 
Table 4 summarises the design variables that need to be balanced in order to maximise the 
effectiveness of drug-carrying hydrogel formulations.  
Table 4. Design variables that influence the effectiveness of hydrogel formulations 
Design criteria Design variable 
Drug molecule Molecular weight and size 
 Ionic charge and functional groups 
 Drug-loading method: post or in situ loading 
 
Hydrogel properties Average molecular weight of polymer 
 Cross-linking density 
 Polymer-drug interactions 
 Biodegradability 
 Sensitivity to stimuli  
 Biocompatibility 
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2. Mucoadhesive polymers for hydrogel formulation 
 
Owing to their capacities to form crosslinked structures that retain water, the most commonly 
utilised hydrophilic polymers are polyacrylates: poly(acrylic acid), PAA; poly(methacrylic acid), PMA; 
poly(hydroxyethylmethacrylate), PHEMA; and, poly(acrylamide), PAM [85]. Other hydrogel-forming 
polymers include: poly(ethylene glycol), PEG; poly(vinyl alcohol), PVA; cellulose derivatives; starch; 
chitosan; hyaluronic acid; pectin; sulphated polysaccharides; sodium alginate; and gelatine. The 
water sorption capacities of these polymers vary from a fraction to several thousand times their own 
weight. Polymeric structures with ionisable moieties are generally more mucoadhesive than non-
ionic macromolecules, Table 5. 
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Table 5. Commonly used mucoadhesive polymers. 
Charge Polymer Application Reference 
Anionic Poly(acrylates) 
 
Insulin vaginal gel [102] 
Poloxamer and polycarbophil 
 
Vaginal gel for immunisation [103] 
Polycarbophil 
 
Vaginal gel for candidiasis [104] 
Carbopol and hydroxypropyl gel  
 
Oral ointment [46] 
Hydroxypropyl cellulose/ carbopol 954P/ poloxamer 
407 
 
Metoclopramide nasal gel [105] 
Hydroxyethyl methacrylate 
 
Diclofenac sodium buccal gel [106] 
Ethyl (hydroxyethyl) cellulose and surfactant 
 
Timolol ocular gel [107] 
Poloxamer 407, hydroxypropyl methylcellulose and 
Gantrez S-97 (polymethylvinylether-co-maleic 
anhydride) 
 
Buccal delivery of 5-fluorouracil [108] 
Hydroxypropyl cellulose; methyl cellulose; 
methylcellulose/Tween 80; hydroxyethyl cellulose; 
hydroxyethyl cellulose/Tween 80 
 
Ciprofloxacin nasal gels [109] 
Poloxamer-hyaluronic acid 
 
Sustained protein delivery [110] 
Pluronic F127 and Pluronic F68 
 
Moxifloxacin ocular gel [111] 
Poloxamers and hyaluronic acid 
 
Acyclovir ocular gel [62] 
Cationic Chitosan and polyethylenimine blend 
 
Gene transfection agent [112] 
Chitosan-g-PEG 
 
Delivery of a bioactive bone 
protein 
 
[113] 
Chitosan-pluronic UV cross-linked system 
 
Delivery of growth factors [114] 
Chitosan cross-linked with glutaraldehyde 
 
Used in breast cancer therapy [115] 
Chitosan-polyethylene oxide semi-IPN hydrogel Oral delivery of antibiotics to the 
stomach 
[116] 
Chitosan 
 
Nasal insulin-loaded hydrogel [117] 
N-[(2-hydroxyl-3-trimethylammonium)propyl] 
chitosan chloride and PEG and αβ-glycerophosphate 
 
Insulin nasal gel 
 
 
[4] 
 
Non-ionic Pectin Ketorolac tromethamine nasal gel [118] 
Carrageenan and acrylic acid Oral delivery of insulin [119] 
 
To effect systemic absorption of incorporated actives, mucoadhesive formulations are often co-
formulated with penetration enhancers. In addition to the opening of tight junctions [3], the 
mechanisms of penetration enhancement are as diverse as drug solubilisation or stabilisation [120], 
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the inhibition of enzymatic action [121], the extraction of a membrane protein, and the removal of 
the outer layer of mucous membrane [122], Table 6.  
Table 6. The role of penetration enhancers in mucoadhesive formulations. 
Mechanism  Example 
Alters mucus rheology: 
reduces the viscosity and 
thickness of mucus and/or 
saliva. 
N-Acetyl cysteine effects a reduction in the viscosity of mucus and 
facilitates the diffusion of FD-4 across the intestinal mucosal 
membrane [123]; Poloxamer reduces the viscosity and elasticity of 
mucus and disrupts the lipid membrane allowing leakage of lipids 
and proteins [105]. 
 
Increases the fluidity of 
the lipid bilayer: disturbs 
intercellular packing 
through interactions with 
lipid and/or protein 
components. 
 
Above the critical micelle concentration, sodium dodecyl sulphate 
(SDS) increases the in vitro penetration of caffeine through porcine 
buccal mucosa [124].  Micelles disrupt barrier properties by 
extracting mucosal lipids [125]. 
 
  
Acts at the tight junctions: 
mimics desmosomes to 
disrupt membrane 
integrity. 
 
 
Confocal imaging has shown the opening of tight junctions of 
intestinal epithelial cells by N-trimethylated chitosan chloride to 
enhance the penetration of 14C mannitol, fluorescently-labelled 
dextran 4400 and ocreotide [126]. 
 
Overcomes enzymatic 
barrier: inhibits peptidases 
and proteases present 
within the mucosa. 
Morishita et al. [127] used the in situ loop method to co-administer 
aprotonin and insulin to the duodenum, the jejunum, the ileum and 
the colon. The most pronounced hypoglycaemic effect was 
observed in the ileum.  
 
 Anionic mucoadhesive polymers  
 
Carboxyl- or sulphate-functionalised polymers have pKa values that are suitable for applications 
within the living host and combine good mucoadhesion properties with low toxicity, which renders 
them potential candidates for mucoadhesive drug delivery [43]. The good mucoadhesive properties 
of poly(acrylic acid) and its weakly cross-linked derivatives (carbomers, polycarbophils) and those of 
sodium carboxymethylcellulose have been attributed to the formation of strong hydrogen bonds 
with mucin [128]. A comparative study by Madsen et al. [42] has shown that while both these 
classes of polymers exhibit rheologically synergistic interactions with mucus, those of the poly(acrylic 
acid)s are most pronounced over the pKa range 4.9-6.7, where the polymers are in their partially 
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deprotonated form. The pH-independent rheologically synergistic behaviour of 
carboxymethylcellulose (CMC), which has been explained by the potential of CMC to retain its coiled 
conformation due to the non-disruption of hydrogen bonding across the pH range [42], has been 
confirmed by Rossi et al. [64].  
Sriamornsak et al. [44] have studied the rheological interactions between mucin and pectin, an 
anionic polymer at neutral pH. In simulated gastric fluid (pH 1.2), and in accord with the behaviour of 
poly(acrylic acid)s, at pH values <pKa (3.2-4.3) the carboxyl groups of pectin are fully protonated, as 
are the sialic acid moieties of mucin, effecting extended hydrogen bonding and demonstrating 
rheological characteristics that indicate entanglement of the pectin with the mucin: the G” 
(dissipative loss modulus)  exceeded G’ (elastic storage modulus), and a substantial decline at low 
frequencies. As the pH is increased to near-neutral (6.8), both the carboxyl moieties of pectin and 
the sialic acid groups of mucin become ionised, leading to the destruction of the hydrogen bonded 
network. The mucoadhesive interactions between the two anionic species are significantly weaker 
since the hydrogen-bonding component of the mucoadhesive interaction is replaced by electrostatic 
attractions that require the involvement of cations present within the aqueous medium.   
 
 Cationic mucoadhesive polymers  
 
Properties of biocompatibility, biodegradability and low toxicity make chitosan – a linear 
polysaccharide derived from the deacetylation of chitin sourced from crustaceans – and its 
derivatives the most extensively used cationic hydrogel polymers [43, 129]. Of significance in 
mucoadhesive drug delivery are the capacity of the primary amino groups of chitosan to participate 
in ionic interactions with the sialic acid and sulphonic acid moieties of mucus and the capability of 
the material to promote the systemic absorption of co-formulated large hydrophilic molecules [5, 
43]. It has been suggested that the penetration-enhancement properties of chitosan are due to its 
capacity to counterbalance the fixed anionic charges of tight junctions, which effects the transient 
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opening of these junctures and allows the transit of otherwise excluded molecules via the 
paracellular route [5, 43]. Accordingly, Boonyo et al. [130] have demonstrated the increased 
capability of the more positively charged trimethylated chitosan (TMC; 40% derivatised) to  enhance 
antigen uptake in mice, as compared with its non-quaternised precursor molecule. However, in the 
design of mucoadhesive TMC-based formulations, the increasing capability of the progressively more 
highly quaternized polymer to enhance penetration must be balanced against the corresponding 
reduction in the capacity of the material to adhere to mucosal surfaces [131]. 
 
 Site-specific mucoadhesive polymers 
 
Given the need for drug delivery at regions distal to administration and the effects of mucoadhesive 
clearance associated with mucus turnover, attempts have been made to address the non-selectivity 
of conventional mucoadhesive systems through the development of cytoadhesive polymer platforms 
[43, 45, 51]. Prime examples of the cytoadhesive component of such platforms are the lectins. These 
naturally occurring proteins play a fundamental role in biological recognition through reversible 
binding to specific carbohydrate residues [27, 43]. On binding to the mucosal surface, the lectins can 
either remain on the cell exterior or, as is the case with receptor-mediated adhesion, become 
internalised via endocytosis. Although endocytosis offers the opportunity for the active cell-
mediated uptake of macromolecular drugs [51], the toxicological and immunological profile of 
lectins places caution on their suggested deployment in drug delivery systems [27, 43].  
The use of polyacrylic acid that had been covalently attached to bacteria (pathogenic E. coli) that are 
known to adhere to the GI mucosal membrane has been shown to effect a significant increase in 
bioadhesion, in vitro, relative to the polymer control [132]. Lee et al. [23] extended the idea of 
polymer-fimbriae adhesion complexes to the adhesion of bioadhesive microspheres to epithelial 
surfaces as an alternative means of facilitating adhesion of hydrogels to mucosal membranes. 
Chapter One 
 
27 
 
An approach to improved mucoadhesive strength has involved the chemical functionalisation of 
hydrophilic polymers (chitosan, polyacrylates or deacetylated gellan gum) to their thiolated 
derivatives. The approach has been rationalised on the basis of the principle that thiols imitate the 
natural behaviour of secreted mucus glycoproteins, which become covalently anchored to the 
mucus layer through the formation of disulphide linkages. On mixing, the thiol groups form covalent 
bonds with the cysteine component of mucus, increasing residence time and improving 
bioavailability [43]. In vitro experiments by Roldo et al. [133] have shown that the attachment of 
thiolated chitosan to mucosal surfaces, as evaluated by total work of adhesion measurements, is two 
orders of magnitude stronger than that of its precursor molecule. It has been claimed that, owing to 
the covalent nature of their interactions with mucus, thiolated structures are less susceptible to the 
effects of changes in ionic strength and/or pH than other mucoadhesive materials [43].  
Sajeesh et al. [134] have reported the surface functionalisation of poly(methylacrylic acid)-based 
hydrogel microparticles with thiol groups. The modified particles although more mucoadhesive 
exhibited reduced swelling capacity and lower insulin encapsulation efficiency. Pritchard et al. [135] 
have shown that the incorporation of thiol functionalities to a polyethylene glycol hydrogel 
promoted cell adhesion due to the increase of interactions involving cysteine groups. A hydrogel 
that is responsive to the presence of human neutrophil elastase,  and hence degradable at sites of 
inflammation, has been prepared by Aimetti et al. [136] via the functionalisation of polyethylene 
glycol with photopolymerisable thiol-ene groups. 
 
1.6. Mucoadhesive-hydrogel drug delivery systems 
 
The mechanism proposed to explain the mucoadhesive behaviour of hydrogels [137] considers the 
miscibility of the mucoadhesive material with the mucus layer in terms of its capability to participate 
in interpolymer interactions. Key to the establishment of such interactions is the capacity of the 
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mucoadhesive to become hydrated at a rapid rate but to a limited extent; all patented 
mucoadhesive materials, Table 7, exhibit this property. 
Table 7. Examples of recently patented hydrogel formulations 
Function of the gel Active Gelling agents Reference 
Teething gel Benzocaine Sodium 
carboxymethylcellulose, 
sodium alginate and xanthan 
gum 
 
[138] 
Gel for dental pain Diclofenac 
sodium and 
chlorhexidine 
gluconate 
Carboxymethylcellulose, acrylic 
acid copolymer and copolymer 
of methyl vinyl ether and 
maleic anhydride 
 
[139] 
Hormonal vaginal gel Estriol Acrylic acid crosslinked with 
allyl surface or divinyl glycol 
 
[140] 
Anti-fungal vaginal gel Econazole 
nitrate 
 
Hydroxyethylcellulose [141] 
Nasal/oral/vaginal pain-relief 
gel 
Diclofenac 
sodium 
 
Xyloglucan and glycerol [142] 
Immunostimulating gels An immune 
response 
modifier 
Polyethylene glycol, 
hydroxyethyl cellulose, 
hydroxymethyl cellulose, 
hydroypropyl cellulose 
 
[143] 
Protective gel  for injured, 
inflamed or surgically 
repairing tissue of the 
ear/nose/throat/limbs/spinal 
cord 
 
 Chitosan, oxidised 
polysaccharides (e.g. 
methylcellulose) 
[144] 
Resistant hydrogel for mucosa 
or natural tissue, e.g. 
cartilage, bone 
 Thiolated chitosan with 
oxidising agent and external 
crosslinking agent 
 
[145] 
 
 Stimuli-responsive hydrogels 
 
The simplest example of a site-specific hydrogel formulation is provided by Nazar et al. [146] who 
formulated a TMC-based hydrogel that may be useful for the intranasal delivery of insulin. The 
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material may be administered into the nasal cavity as a solution which undergoes a sol-to-gel 
transition at the physiologically relevant temperature to a structure that is capable of acting as a 
device for the controlled release of co-administered insulin. Systematic variations of the proportions 
and chemical nature of the polymeric component allows the fine control of the gelation temperature 
to that appropriate to the target site, as has been demonstrated with not only the system described 
by Nazar et al. [146] but also with those developed by Khan et al. [147] (chitosan, glycerophosphate 
and hydroxyl propyl methyl cellulose gel for the intranasal delivery of ropinirole), Ved et al. [148] 
(poloxamer 407, phosphatidylchonine and n-tridecyl-(-β-)maltoside gel for the intranasal delivery of 
zidovudine), Nguyen et al. [149] (poly(amidoamine)-poly(ethylene glycol)-polyamidoamine) triblock 
copolymer hydrogels for oral drug delivery), and Shastri et al. [111] (poloxamers Pluronic F127 and 
F68 gel for the ophthalmic delivery of moxifloxacin hydrochloride).  
To synchronise the drug-release profile of carrier systems with variations in the physiological 
environment, much research work has focussed on systems capable of modulating their release 
profile by sensing changes at the target site [150]. Such systems may adjust their swelling behaviour, 
permeability, network structure or mechanical strength [85] by reacting to internal or external 
stimuli [84].  
Sharma et al. [151] have described the development of stimulus-responsive drug release systems 
that exhibit pulsatile release. Such hydrogels may prove useful in the treatment of diseases that 
require on-demand or rhythmic medication (amongst others hypercholesterolemia, asthma, cancer, 
duodenal ulcer, arthritis, diabetes, neurological disorders, cardiovascular diseases, and irritable 
bowel syndrome). Driven by this demand hydrogel devices have been formulated that respond to 
levels of glucose, enzymes, antibodies or pH.  
Several glucose-sensitive hydrogels have been investigated. The systems reported to date are 
categorised into those that: respond to the variations in pH that accompany the  enzymatic oxidation 
of glucose to H2O2 (based upon glucose oxidase [152]); depend on the competitive binding of glucose 
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(concanavalin A [153]); form a reversible complex with glucose (phenylboronic acid [154]); and, are 
based on a glucose-binding protein [155].   
Enzyme-responsive hydrogels have been reviewed by Roy et al. [156]. Most promising appear to be 
those that employ protein- or peptide-based crosslinkers that become hydrolysed on exposure to 
proteases, leading to gel degradation and the consequent release of the therapeutic component. 
Miyata et al. [157] have developed an antigen-responsive hydrogel for the pulsatile release of 
protein. This system is designed such that competitive binding of free rabbit IgG antigen with 
antibodies in the hydrogel compromise the antigen-antibody crosslinks within the antigen-antibody 
semi-interpenetrating network leading to reversible swelling of the system and to the release of the 
active. 
Since at pathological conditions there is often interplay of more than one stimulus, early work on 
stimulus-responsive hydrogels has been superseded by the quest for multi stimuli-responsive 
systems. An example of a dual-stimulus responsive biodegradable hydrogel is provided by a network 
of gelatin and dextran: incorporated lipid microspheres acting as drug micro-reservoirs are released 
by the combined action of α-chymotrypsin and dextranase, but not by either enzyme acting in 
isolation [158]. Another example is provided by Guo et al. [11] who have reported the co-
formulation of carboxymethyl chitosan and poly(N-isopropylacrylamide) to a pH- and temperature-
sensitive amphoteric polyelectrolyte hydrogel for the oral delivery of drugs.  
Blanchette et al. [27] have investigated the effects of copolymer composition and pH of the 
surrounding medium on the network structure of a series of hydrogels. Of the systems investigated, 
an equimolar hydrogel of poly(methacrylic acid) (PMA) and ethylene glycol (EG) exhibited the 
greatest pH-dependent change in mesh size. It has been suggested that, since the acidic 
environment of the stomach would maintain a collapsed network that inhibits the release of the 
active, this responsiveness may be useful for the enteric delivery of oral actives [27]. Wang et al. 
[159] have developed a multi-stimulus responsive hydrogel formulation by utilising a copolymer that 
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had been prepared from the pH and temperature-sensitive (2-dimethylamino)ethyl methacrylate 
and the glucose-sensitive 3-acrylamidephenylboronic acid. The high specificity and capacity to 
respond to physiological changes that are specific to each disease state render stimulus-responsive 
hydrogels the delivery systems of choice for further development. However, before such systems 
can be adopted in the clinic, considerable advances are needed in the design of synthetic 
formulations that are capable of adapting their properties in a pre-specified manner and in 
accordance with specific interactions with biomolecules or with other markers characterising a 
disease state [156]. 
Drug release is most frequently observed during the swelling of the hydrogel structure. However, 
drug release may occur as the gel contracts and liquid along with dissolved drug are expelled from 
the formulation. Such hydrogels have been shown, by Gutowska et al. [160], to respond to changes 
in temperature and/or pH and to be amenable to formulation into systems that exhibit controlled 
swelling-deswelling kinetics. 
 Self-assembling peptide nanofibre hydrogels 
 
Upon introduction to electrolyte solutions, certain peptides comprising of alternating hydrophobic 
and hydrophilic amino acids self-assemble into interconnected nanofibers (diameter 10-20 nm), 
which become then organised into highly hydrated hydrogels with pore sizes in the range 5-200 nm. 
Due to their peptide composition, these structures are assumed to be more biocompatible and to 
have a lower potential to induce adverse effects than conventional hydrogels. The sol-gel transition 
occurs at physiological conditions and the high internal hydration provides an environment that can 
accommodate bioactive molecules and/or cells [161, 162]. A recent example is provided by a self-
assembling peptide hydrogel that has been shown to effect the localized delivery of curcumin over 
sustained periods of time [163]. In another example, the sustained and controlled drug release of 
docetaxel has been effected from a  hybrid hydrogel composed of Fmoc-diphenylalanine (Fmoc-FF) 
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peptide, konjac glucomannan (KGM) and b-mannanase [164]. In addition to their application in drug 
delivery, and because of their capability to support cell adhesion, self-assembling peptide hydrogel 
scaffolds have been applied to tissue engineering functions, including bone and cartilage 
reconstruction, heart-tissue regeneration, and angiogenesis [165, 166], but their efficacy in mucosal 
drug delivery has yet to be determined. 
 Superporous hydrogels and complexes, and interpenetrating 
networks 
 
The need for mucoadhesive hydrogels that exhibit rapid swelling to equilibrium dimensions has 
provided the impetus for the development of open-channelled network structures: superporous 
hydrogels (SPH) and SPH composites (SPHC) [167-169]. The improved aqueous permeability and 
biocompatibility of SPH systems relative to those of other hydrogel structures is counterbalanced by 
poor mechanical strength, which is markedly improved in  SPHC structures, such as those prepared 
by adding croscarmellose sodium (Ac-Di-Sol) to the hydrogel mix [169, 170]. The impact of 
mechanical properties on the performance of such systems has been studied by Dorkoosh et al. 
[171, 172] who suggested that the opening of tight junctions is caused by the mechanical pressure 
produced by the swelling of SPH and SPHC polymers. 
Attempts to improve the mechanical properties and resilience of SPHs and SPHCs have led to the 
development of interpenetrating networks (IPNs). These systems are formed through the mixing of 
cross-linked polymer networks at the molecular-segment level: if only one polymer is cross-linked 
and the other is linear, the system is termed semi-IPN; if both polymers are cross-linked, the system 
is described as full-IPN [170].  
Tang et al. [169] has shown that SPHCs containing Carbopol adhere more rapidly to intestinal 
mucosa and demonstrate higher mucoadhesive capacity than congeners prepared in the absence of 
this carbomer. Work by Kim et al. [173] has led to the development of third generation SPHs: 
poly(acrylic acid-co-acryl-amide)/poly(ethylenimine), P(AA-co-AM)/PEI, semi-IPNs that possess good 
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mechanical strength (comparable with that of SPHCs), which is claimed to be bestowed by the high 
degree of molecular entanglement between the cationic PEI and the anionic PAA. Yin et al. [174] 
have synthesised SPH-IPNs of poly(acrylic acid-co-acrylamide)/carboxymethyl chitosan that are 
claimed to display an enhanced loading capacity for insulin, and improved in vitro mucoadhesive and 
mechanical properties as compared with previous generation materials.  
Verestiuc et al. [175]   have prepared a series of optically transparent semi-IPN networks by the free 
radical polymerisation of N-isopropylacrylamide (NIPAAm) in the presence of chitosan (CS) using 
tetraethyleneglycoldiacrylate (EGDA) as the crosslinking agent. Up to a plateau CS/NIPAAm ratio of 
0.46, the proportion of chitosan that could be incorporated into the matrix was found to increase as 
the crosslinking density of the network was increased. Also, it was observed that as the chitosan 
content and crosslinking density increased, the phase transition temperature of the hydrogels 
became less well defined and shifted towards lower temperatures and that  the degree of swelling 
of the hydrogel fluctuated from ca. 100% at basic pH to over 2000% at acidic pH. Reinforced 
biocompatible systems, such as those obtained via the formulation of SPHCs with IPNs, exhibit 
improved biocompatibility without compromising the stability and mechanical strength of the 
hydrogel.  
 Micro- and nano-gels 
 
Potential applications in injectables, and the demand for drug-delivery systems that respond rapidly 
to stimuli and exhibit trigger release, have led to the development of small-sized gel systems. 
Structures ranging between 50 nm and 5µm in average diameter [176] are being investigated for 
their potential in peptide and protein drug delivery, with much of the work focusing on those that 
exhibit stimuli-dependent transitions; systems that exhibit responsiveness to temperature, 
electrostatic environment, metabolic processes and products, external fields (light, ultrasound, 
magnetic), and degradation have all been considered [177]. Such miniaturised drug-carrying vehicles 
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are claimed to be minimally invasive if administered via the oral or nasal routes, or if injected into 
patients [93].   
Drug delivery by means of hydrogel nanoparticles (nanogels; <200 nm) [178] has received 
considerable attention  [1, 178-180]. Such materials are considered to possess the combined 
features of hydrogels and nanoparticles: hydrophilicity, flexibility, versatility, high capacity to 
accommodate water, biocompatibility, long circulation time, and the potential to be targeted 
actively or passively to the site of action [88]. These properties are often tuneable to the demands of 
each drug-delivery application by altering proportions of cross-linking density, chemical 
functionalisation, surface-active components and stimuli-responsive constituents [178]. Vinogradov 
et al. [179] who investigated a cross-linked cationic polymer nanogel network for the delivery of an 
active form of a cytotoxic anticancer drug claims that the formulation achieved a 90% protection of 
the drug from enzymatic degradation and a fourfold increase in transcellular transport across Caco-2 
cell monolayers while enhancing drug targeting and internalisation at the desired site. Prego et al. 
[1] have shown that chitosan-coated nanogels display a significant capacity to enhance the intestinal 
absorption of salmon calcitonin in the rat, which renders them candidate structures for the 
treatment of hypercalcemia. In another example, Nukolova et al. [181], who loaded cytotoxic drugs 
into folate-decorated nanogels and tested them on an animal model of ovarian cancer, report that 
these delivery systems improve the anti-tumour action of the chemotherapeutant and reduce its 
side effects as a result of the combined benefits imparted by high loading capacity, steric-
stabilisation and tumour specificity.  
Li et al.[182], in their effort to design a system for the delivery of paclitaxel (an anticancer drug of 
poor aqueous solubility), prepared a micellar nanogel formulation by cross-linking Pluronic F127 
with polyethylenimine and poly(butylcyanoacrylate). This formulation exhibited improved blood-
plasma stability and a more sustained drug release profile than corresponding micelles of Pluronic 
F127.  
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Rationalised by the principle that the hydrophobic internal cavity of cyclodextrins (CDs) renders it a 
suitable host for certain drug molecules, Kettel et al. [183] have incorporated reactive CDs into 
aqueous nanogels. The inclusion complexes that formed exhibited excellent colloidal stability in 
water, and were found to be amenable to regulation of their nanogel size (hydrodynamic radius) 
through variations in the ratio of incorporated CD. 
Barbu et al. [184] prepared hybrid nanoparticles (10–70 nm) that combine the temperature 
sensitivity of N-isopropylacrylamide or the good swelling characteristics of 2-hydroxyethyl 
methacrylate with the susceptibility of chitosan to lysozyme-induced biodegradation, and the 
materials have been investigated for their capability to act as controlled release vehicles in 
ophthalmic drug delivery. Studies on the effects of network structure upon swelling properties, 
adhesiveness to mucosal surfaces and biodegradability, coupled with in vitro drug release 
investigations employing ophthalmic drugs with differing aqueous solubilities, have identified 
nanogel compositions for each of the candidate drug molecules.  
 
1.6. Conclusions 
 
As compared with other structures such as liposomes or micelles, polymeric hydrogels are more 
stable, simpler to prepare and to scale-up, and offer considerable promise as systems for controlled 
drug release. Additional to biodegradability, loading capacity, immunogenicity and toxicity, the 
choice of the polymeric matrix is dictated by its capability to respond to physiological stimuli and/or 
exhibit mucoadhesion. The organic nature of hydrogel-forming polymers offers the advantage of 
allowing blending with other polymers (such as in the formation of interpenetrated networks) or 
conjugation with molecules (such as azoreducible crosslinkers), which in turn afford a significant 
degree of control over the drug release profile and impart targeting specificity. Also, the internal 
porosity may be manipulated such that hydrogels meet specified criteria that influence drug release 
profiles.  
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1.7. Future Perspective 
 
Recent progress in nanoformulation has seen the promise of hydrogel structures that may help the 
incorporated active to cross biological barriers, such as those of the eye, but the challenges of 
nanogel design for such applications are integral to those associated with the detailed appreciation 
of specific disease-induced changes in the structure and functionality of the target barrier. Early 
work utilising lectins has highlighted the potential for the combination of specific materials and cell-
based delivery strategies (e.g. complexation with antibodies, cell-penetrating peptides or cell-
specific ligands) and may evolve into another tactic for improved organ or even cell targeting.  
Hydrogel systems that are formulated from biocompatible polymers are now being customised by 
tailoring their physicochemical characteristics not only to the demands for efficient drug 
incorporation and controlled release but also to those for site specificity, by building into the 
hydrogel structure response mechanisms that are only triggered by the target physiological 
environment. The design of hydrogel formulations that release therapeutic agents only once they 
have sensed a disease-specific biomarker represents the next stage of development. 
 
1.8. Aim and objectives  
 
Towards the development of a drug-delivery vehicle for the nasal delivery of insulin, a systematic 
series of N-trimethyl chitosan will be co-formulated with poly(ethylene glycol) and glycerophosphate 
into a thermosensitive hydrogel structure. Rheological evaluations will allow the optimisation of the 
sol-to-gel transition properties such that they occur over optimally brief timescales and at 
physiologically relevant temperatures.  In vitro experiments will allow the evaluation of the 
capacities of the formulation to affect the opening of modelled tight junctions and to release its 
therapeutic content under conditions that mimic those of the nasal environment. In parallel, 
spectroscopic and analytical investigations will assess the structural integrity and conformational 
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order of the incorporated insulin over a specified time scale. Finally, the in vivo potential of the in 
situ thermogelling nasal formulation to act as a once-a-day dosage form for the intranasal delivery of 
insulin will be investigated in the diabetic-rat model.  
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Thermosensitive hydrogels for nasal drug delivery: the 
formulation and characterisation of systems based on N-
trimethyl chitosan chloride. 
 
Abstract 
 
Towards the development of a thermosensitive drug delivery vehicle for nasal delivery, a systematic 
series of N-trimethyl chitosan chloride polymers, synthesised from chitosans of three different 
average molecular weights, have been co-formulated into a hydrogel with poly(ethylene glycol) and 
glycerophosphate. Rheological evaluations have shown that hydrogels derived from N-trimethyl 
chitosan with a low degree of quaternisation and high or medium average molecular weight exhibit 
relatively short sol-gel transition times at physiologically relevant temperatures. Also, the same 
hydrogels display good water-holding capacity and strong mucoadhesive potential, and their 
mixtures with mucus exhibit rheological synergy. An aqueous hydrogel formulation, derived from N-
trimethyl chitosan of medium average molecular weight and low degree of quaternisation, appears 
particularly promising in that it exhibits most favourable rheological and mucoadhesive behaviour 
and a sol-gel transition that occurs at 32.5 °C within 8 min. 
 
2.1. Introduction 
 
Nasal drug delivery for systemic effects is an historic administration route [185], and owing to the 
avoidance of the first-pass effect, the nasal mucosal membrane presents a potentially useful site for 
the delivery of proteins and peptides [186-190]. However, there are drug-delivery challenges that 
need to be overcome if intranasal drug delivery is to become the method of choice for the delivery 
of therapeutic agents, namely: mucosal membranes pose a substantial barrier to the absorption of 
macromolecules [191]; proteolytic enzymes in nasal secretions impact upon the  bioavailability of 
proteins and peptides [185]; and, nasal residence, as determined by mucus turnover time, is limited 
to approximately 15 - 20 minutes [30, 185]. Drug-delivery strategies that have been explored in 
efforts to overcome these challenges are as diverse as the modification of the peptide structure 
[192], the inhibition of the ciliary beat frequency [185], the employment of permeation or 
absorption enhancers, and the utilisation of mucoadhesive polymers [105]. 
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Research efforts into the employment of mucoadhesive viscoelastic hydrogels in nasal drug delivery 
are rationalised in terms of their potential for prolonging the residence time of the active on the 
mucosal surface. Such systems lend themselves to administration as sprays or drops and may be 
designed such that they undergo a sol-gel transition at the temperature of the site of deposition (32 
– 35 °C, table 8) [31, 32], with the implication that the increased viscosity and rheological synergy of 
the resulting mucus/mucoadhesive system effects prolonged residence at the site of action [4, 23, 
43, 53, 193].  
Table 8. Distribution of temperature in the nasal passageway during quiet breathing at room 
temperature (25 °C, 8.06 mg H2O/l)[32], and the areas of dosage form deposition by nasal drops 
and spray [194] 
Location Inspiration 
temperature °C 
Expiration 
temperature °C 
Deposition of nasal 
dosage forms 
Nasal vestibule 25.3 34.2  
Nasal valve 29.8 35.1  
Anterior turbinate 
area 
32.3 35.1 Targeted by nasal 
sprays and drops  
Nasopharynx 33.9 36.2 More deposition by 
nasal drops  
 
Amongst the mucoadhesive viscoelastic hydrogels studied to date, those structured around chitosan 
– a biocompatible and biodegradable natural polysaccharide – have shown particular promise since 
they facilitate the paracellular transport of large molecules across the mucosal surface by opening 
tight junctions [195-199]. In particular, the thermosensitive chitosan/glycerophosphate gels, 
developed by Chenite et al. [200], were shown to be suitable for the delivery of sensitive biological 
materials such as proteins and gene-based therapeutics. However, despite promising results, 
chitosan presents limitations in that it is only soluble and active in acidic environments, when in its 
protonated form [126]. For this reason, and due to the fact that the chitosan-based thermosensitive 
gels so far developed undergo only a slow sol-gel transition at physiological pH [201], chitosan has 
been substituted by its positively charged derivative N-trimethyl chitosan chloride (TMC) [202]; this 
retains the key qualities of the parent polymer but presents improved solubility profile, enhanced 
mucoadhesive properties and a significant absorption enhancing effect over a wide pH range [203] 
as well as enhancing the properties of the thermosensitive formulations [4, 200, 204]. TMC/GP 
hydrogels have been previously studied for parenteral drug delivery [201, 205]. However, there are 
scarce reports on their use for intranasal administration. Therefore, the current work aims at 
investigating this specific application, studying the effect of molecular weight (MW), degree of 
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quaternisation (DQ) of TMC, and hydrogel composition on the thermosensitivity and rheological 
behaviour of nasal formulations. The objective is to optimise a system able to undergo a sol-gel 
transition in the temperature range 32-35 °C, thereby allowing a stable liquid state to be maintained 
at storage temperature and prior to usage, easing administration via nasal spray or drops. This 
system should gel at 32-35°C, representative of the nasal environment [31], and provide a synergic 
effect in contact with the nasal mucus that can guarantee prolonged residence time and show the 
required rheological characteristics. These have been identified to be specific  apparent viscosity 
(350 mPa s) and viscoelasticity (200 Pa) values that significantly reduce the mucociliary transport 
rate (MTR) [206]. 
 
2.2. Materials 
 
Chitosans (low viscosity, 150 kDa, degree of deacetylation (DD) 95 - 98 %; medium viscosity, 400 
kDa, DD 84 - 89 %; and, high viscosity, 600 kDa, DD 75 - 85 %), poly(ethylene) glycol 4000 (PEG) and 
poly(acrylic acid) (PAA) were obtained from Fluka, UK. Glycerophosphate (GP; equimolar mixture of 
α and β isomers), tristearin (TRIS) and porcine-stomach mucin were purchased from Sigma-Aldrich 
Inc., UK.  Methyl iodide and 1-methyl-2-pyrrolidinone were sourced from Acros Organics, Belgium. 
All other chemicals were obtained from Fisher Scientific, UK, and used as received.  
 
2.3. Methods 
2.3.1. Synthesis and characterisation of N-trimethyl chitosan chloride  
 
TMC was synthesised via the reductive methylation of chitosan of three different average molecular 
weights (low, L; medium, M and high, H) according to the method described by Sieval et al. [202]. 
Different degrees of quaternisation were obtained by employing a one and a two step synthesis 
method (e.g. L1 or L2) as described by Hamman et al. [207]. 
Briefly, chitosan (2 g) and sodium iodide (4.8 g) were dissolved in 1-methyl-2-pyrrolidinone (80 ml) 
by stirring for 30 min in a water bath at 60°C. Sodium hydroxide (11 ml, 15% w/v) and methyl iodide 
(11.5 ml) were added to the solution and stirred for 1 h. The product was precipitated using ethanol 
and diethyl ether and isolated by centrifugation. The precipitate was washed with ethanol:ether 3:1 
(30ml x 3). For the one step synthesis the product was dissolved in NaCl solution (40ml, 10%) and 
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stirred over night. On subsequent precipitation with the two solvents and centrifugation the 
material was dissolved in 40 mL of deionised water and dialysed for 72 h before freeze-drying.  
The two step synthesis differs in the later stage as the initial precipitate was again dissolved in 1-
methyl-2-pyrrolidinone (80 ml) with sodium iodide (4.8 g). Once dissolved methyl iodide (7 ml) and 
sodium hydroxide (11 ml, 15% w/v) were added and stirred in a water bath at 60 °C for 30 min. An 
additional 2 ml of methyl iodide and 0.6 g of NaOH pellets were also added and left for 1h stirring. 
The material produced was washed and isolated as before. 
The degree of quaternisation was calculated from corresponding 1H NMR spectra (D2O; 80 °C; Jeol  
400 MHz spectrometer, Bruker, Japan) using Eq. (1) [208]: 
Equation 1. Degree of quaternisation. 
     
 ∫    
 ∫        
   
 
 
                                        (1) 
where DQ is the degree of quaternisation, and ∫3.4 and ∫4.7 - 5.4 are the respective integrals of the 
trimethyl amino group absorption (3.4 ppm) and of the collective 1H resonances in the range 4.7 - 
5.4 ppm [202] respectively. Infrared spectra were recorded using a Varian 640-IR FTIR (Varian Inc, 
Palo Alto, USA; 400 – 4000 cm-1, absorbance mode, 4 cm-1 resolution, 32 scans). Thermogravimetric 
analysis (TGA) was performed using a TGA-Q50 (TA Instruments, New Castle DE, USA; N2 
atmosphere, 10-600 °C, 10 C min-1). The crystalline order of dry TMC polymers was examined using 
an X-Ray diffractometer (Bruker D8, Karlsruhe, Germany; Ni-filtered CuKa1, wavelength (λ) = 
0.154059 nm at 40 kV, 40 mA, scan speed =1 deg min-1, 2θ range 2-50°). Fourier Transform Raman 
(FT-Raman) spectra were recorded using a Bruker EQUINOX 55 spectrometer (Karlsruhe, Germany) 
equipped with a (D) FRA-106/S attachment: Raman excitation was by means of a A R510 diode 
pumped Nd:YAG laser operating at 1064 nm (with a maximum output power of 500 mW); optical 
filtering reduced the Rayleigh elastic scattering and, in combination with a CaF2 beamsplitter and a 
high sensitivity liquid N2-cooled Ge-detector, allowed the Raman intensities to be recorded over the 
range 50 - 3300 cm-1 in the Stokes side.  
 
2.3.2. Formulation and characterisation of hydrogels 
 
For each synthesised TMC polymer, four TMC solutions with a concentration of 4.5 % w/v and a total 
volume of 4 mL were prepared in deionised water. To the TMC solutions, PEG 4000 (270 mg) was 
added with stirring until a clear solution was obtained.  In parallel, a series of aqueous GP solutions 
of specified concentrations (6.25, 12.5, 25 and 50 % w/v) was also prepared. All solutions were 
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placed in an ice bath for 10 min. Hydrogels were prepared by the dropwise addition (under stirring) 
of 1 mL aliquots of the cold GP solution to each of the cold TMC/PEG solutions, gel compositions are 
given in table 9 
Table 9. The composition of TMC hydrogel formulations 
Component Final concentration (% w/v) 
TMC (L1, L2, M1, M2, H1, H2) 3.6 
PEG 4000 5.8 
GP 1.25, 2.5, 5, 10 
 
 Visual determination of sol-gel transition time  
 
The sol-gel transition time was determined by visual inspection, using the inversion method [209]: 
TMC/PEG/GP solutions (5 mL) were incubated in a water bath at 35 °C, or left at room temperature 
for the duration of the test, and at 30 s intervals the vials were inverted to assess the flowage of the 
sample; the sol and gel phases were respectively characterised by the sample exhibiting liquid-like 
flow or becoming immobile. All experiments were carried out in quadruplicate. 
 
 Rheological investigations 
 
Rheological analysis (cone and plate geometry; cone dimensions 2° and 60 mm diameter) was 
performed using an AR2000 controlled-stress rheometer (TA Instruments, Leatherhead, Surrey, UK) 
interfaced to TA Rheology Data Analysis software (V.5.1.42, TA Instruments, Leatherhead, Surrey, 
UK). Aliquots of test samples were loaded onto the rheometer platform and allowed to equilibrate (5 
min) at the temperature of the experiment. Strain sweep measurements at 1 Hz (n=1) allowed the 
determination of the linear viscoelastic region (LVR); where appropriate, further rheological 
investigations were performed within this region. 
 
 Assessment of in vitro sol-gel transition time and temperature 
 
To assess the physiological relevance of the sol-gel transition time of TMC hydrogels, rheological 
evaluation tests were performed at 15 °C and at 35 °C; temperatures that respectively correspond to 
that of cool storage and that of the surface of the nasal mucosa [31]. For formulation M1-2.5GP, the 
experiment was also carried out at 25, 27, 29, 31, and 33 °C, to study the effect of temperature on 
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gelation time. A multiwave frequency test allowed the determination of the frequency-independent 
gelation time from the intersecting curves tan δ versus time. A time sweep (1 °C min-1) was 
performed over the 10 °C – 40 °C temperature range, at a fixed frequency (0.01 Hz) and a fixed 
amplitude of applied stress (0.02 Pa). The gelation temperature was determined by monitoring the 
variations in the elastic (G’) and viscous (G”) moduli: gelation temperature was identified by the 
transition from a prevalently viscous state (G” > G’) to one that is prevalently elastic (G’ > G”). All 
experiments were carried out in quadruplicate. 
 
2.3.3. Preparation of mucus/hydrogel systems 
 
Since the capability of hydrogels to form true blends with mucus is a property of some importance to 
the in vivo mucoadhesion behaviour of the system and also its influence upon the mucociliary 
transport rate (MTR), hydrogel/mucus mixtures for rheological and other investigations were 
prepared by mixing the hydrogel formulations with simulated nasal electrolyte solution (SNES: 7.45 
mg mL-1 NaCl; 1.29 mg mL-1 KCl and 0.32 mg mL-1 CaCl2.2H2O; adjusted to pH 5.5 with 1M aqueous 
HCl and mixed with 1 mg mL-1 aqueous mucin in the 5:1 (w/w) ratio). Controls were provided by 
similar, 5:1 (w/w), mixtures of hydrogel and water and also of water and mucin. 
 
 Viscosity, viscoelasticity and rheological synergy 
 
Frequency sweeps (10 - 0.01 Hz, 20 readings) at 35 °C on hydrogel/mucus mixtures allowed the 
determination of the complex modulus, G*; evaluation studies confirmed there was no significant 
difference between the 20 readings of G*. Measurements of G’ and G” were also averaged over 20 
readings. The synergistic effect of hydrogel and mucin mixtures was evaluated using Eq. (2) [61]:  
Equation 2. Relative G’. 
             
                    
            
        (2) 
where      ,      ,       represent the respective elastic moduli of hydrogel–mucin mixtures, 
hydrogel, and mucin; relative G” was calculated similarly.  
 
The apparent viscosities (η) of the hydrogel and of the hydrogel-mucin samples were monitored for 
1 min under constant shear rate (100 s-1); experiments were repeated four times, and 
measurements are reported as the average of those taken during the final 30 s of each 
measurement period. Oscillatory measurements (40 - 0.01 Hz; constant applied stress, within the 
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LVR) allowed the investigation of the effects of frequency on the dynamic moduli, G’ and G”, and 
provided the means for the assessment of rheologically synergistic effects. 
 
2.3.4. Water-holding capacity of hydrogel formulations 
 
The capacity of the hydrogels to hold absorbed water was evaluated as a function of molecular 
weight and the degree of quaternisation. Discs were cut (diameter 15 mm, cross-sectional thickness 
5 mm) from freeze-dried hydrogel and dried at 60°C for 24 h. These were placed into dissolution 
baskets, which were then immersed into pH 5.5 SNES-mucin (20°C) for specified periods of time. The 
baskets were lifted out of the solution and each weighed following the repetitive wiping of excess 
surface liquid (filter paper) until three consecutive readings gave identical mass readings. The water-
holding capacity (WHC) was calculated from Eq. (3): 
Equation 3. Water holding capacity. 
     
       
  
          (3) 
where MMax is the maximum mass of the hydrated gel, and M0 is the mass of the dry gel at time 0. 
 
2.3.5. Mucoadhesive behaviour 
 
A TA-XT2 Texture Analyser (Stable Micro Systems, Surrey, UK) in adhesion mode allowed the 
determination of the total work required to detach the lyophilised hydrogels from isolated rat 
intestinal mucosal tissue [210]. Positive and negative controls were provided by samples of poly 
(acrylic acid) and tristearin, respectively.  Test materials or controls were attached to the lower tip of 
the texture-profile-analyser probe using double-sided adhesive tape. The substrate was Wistar rat 
intestinal mucosa that had been isolated surgically and kept under mucin solution (pH 5.5). For force 
measurements, the tip was lowered onto the surface of the mucosa, a force of 0.02 N was applied 
for 2 min, to ensure intimate contact between the mucosal surface and the hydrogel sample, and 
the probe was raised at a constant speed of 5.00 mm s-1 to a return distance of 300 mm. The total 
work of adhesion (TWA) was calculated from the area under the force versus distance curve and 
reported as the average of four measurements. Data collection and manipulation was by means of 
an interfaced XTRA Dimension software package. 
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2.3.6. Statistical Analysis 
 
The statistical significance of the differences between rheological and mucoadhesive parameters of 
the range of TMC/PEG/GP hydrogel formulations was tested by one-way analysis of variance 
(ANOVA) and further by the multiple comparison Tukey-Kramer test. Differences were considered to 
be significant if p < 0.05. 
 
2.3.7. Physicochemical characterisation of hydrogels 
 
The porosity and surface area of the lyophylised hydrogels were determined using the Brunauer-
Emmett-Teller (BET) method. The specific surface area (SBET), the pore volume (VP) and the pore size 
distribution of the samples were determined (Quantachrome Autosorb-1 instrument; Boynton 
Beach, FL, USA) from the adsorption/desorption isotherms of nitrogen at -196 °C. The surface area 
was obtained following the BET (Brunauer–Emmett–Teller) procedure with six relative pressures of 
nitrogen in the range 0.05 p0 – 0.3 p0. Pore size distribution was estimated using the BJH (Barrett, 
Joyner and Halenda) method. Total pore volume was determined (out-gassed samples; room 
temperature, 10 h, vacuum) at P/P0 = 0.995. The surface morphology and internal structure of 
hydrogels were visualised by scanning electron microscopy (SEM; JEOL SEM (JSM-6060LV, JEOL Ltd, 
Japan; working distance 12 - 14 mm at 10 Kv, spotsize 35 μm): flat surface cross-sections of dried 
samples were prepared using a sharp blade and imaged under vacuum after 3 min of palladium/gold 
sputtering; displayed images are at 3000× magnification.  
 
2.4. Results and Discussion 
 
2.4.1. TMC synthesis and characterisation 
 
Consequent to the quaternisation reaction, vibrational spectra exhibited the features that 
differentiate TMC polymers from their precursor chitosans.  Indicative of the destruction of residual 
amidic linkages during the quaternisation reaction, Raman spectra (Fig. 3) showed that the intense 
CH3 absorption of acetamide groups (1380 cm
-1), the amidic carbonyl band (1657 cm-1) and the weak 
amidic N-H strech ( 3367 cm-1) all disappeared on quaternisation [211, 212]. Infrared spectra (Fig. 3) 
showed the characteristic band (3300 - 3500 cm-1) that is consistent with the presence of hydrogen 
bonded –NH2 and –OH functionalities. As expected, the intensity of the amino group bend, at 1597 
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cm-1, weakened on quaternisation. Indicative of the specificity of the reaction, primary and 
secondary alcohol absorptions (1102 - 1082 cm-1) appear little changed following quaternisation 
[204]. Consistent with the introduction of methyl moieties, the C-H stretching bands (2900-3000 cm-
1) and bending deformations (1470-1500 cm-1) appeared to become more intense with increasing 
degree of quaternisation. 
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Figure 3. Left: FT-Raman spectra of chitosan (CH) and TMC polymers (L, low; M, medium and H, high molecular weight; 1, one step synthesis and 2, two 
step synthesis). Right: FTIR spectra of (a) low molecular weight chitosan, (b) L1 and (c) L2.
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The DQ of the synthesised TMC polymers, as calculated from 1H-NMR experiments [202], is 
presented in Table 10, along with T50% values from thermogravimetric investigations.  In accord with 
expectation [213], higher DQ polymers exhibited increased thermal stability relative to their 
respective congeners; a similar trend of increasing thermal stability was observed with increasing 
average molecular weight.   
Table 10. Degree of quaternisation of N-trimethyl-chitosan chloride polymers synthesised and the 
temperature required to reduce the respective weight by 50%, T50%, as derived via 
thermogravimetric analysis. The indexes 1 and 2 refer to the number of steps employed in the 
synthesis of chitosan. 
TMC 
Chitosan 
average molecular weight 
DQ % T50 % / °C 
H1 
High 
25.6 356 
H2 53.9 380 
M1 
Medium 
32.8 323 
M2 61.3 383 
L1 
Low 
37.0 308 
L2 54.6 322 
 
Consistent with the thermal-stability effects,  XRD experiments showed the increased crystalline 
order in TMC samples relative to that of their precursor chitosans, as is indicated by the appearance 
of pronounced bands at 2 19.4°, 23.4° and 32.0°, Fig. 4, and the corresponding disappearance of 
the characteristic chitosan peak at 2 = 11° [214, 215].  
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Figure 4. XRD patterns of TMC polymers  (H, M and L denoting high, medium and low Mw 
respectively and 1 and 2 denoting one or two step synthesis respectively) 
 
2.4.2. Characterisation of hydrogel formulations 
 
 Determination of gelation time and temperature  
 
The performance criteria of the nasal-delivery formulations are imposed by the physiological 
temperature of the nasal cavity (32 - 35 °C [31]) and by the mucociliary clearance time (half life ca. 
21 min [76]), which correspondingly specify the temperature range and time limits for the sol-gel 
transition. The application of the inverted-tube test coupled with rheology investigations allowed 
the determination of the influence of GP concentration on gelation temperature and gelation time, 
Fig. 3.  
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Figure 5. Rheological (black) and observational (white) gelation time, and rheological gelation 
temperature of TMC/PEG/GP  hydrogel formulations (e.g. M1-2.5GP, hydrogel formulated with 
medium molecular weight TMC, synthesised by one step procedure and containing 2.5% GP). 
Results are given as mean ± SD (n=4). 
 
The data for TMC formulations based on low MW chitosan are not shown as they do not exhibit gel-
like behaviour over the investigated range of GP concentrations, due to the short polymeric chain 
which offers limited chances of physical entanglement and hydrophobic interactions. The co-
formulation of PEG molecules imparted considerable improvement on the capacity of networks to 
form gels. Amongst the formulations tested, only hydrogel M1 (2.5 % w/v GP) exhibited its sol-gel 
transition at a physiologically relevant temperature (32.5 ± 0.4 °C; Fig. 5). The gelation time of the 
same formulation has been determined at 6.3 ± 0.6 min, which is well below the time for mucociliary 
clearance. The gelation time of this formulation was tested in the 25-35 °C range to ascertain that it 
would be effective even if the temperature of the nasal cavity was different (Table 11).  
Table 11. Effect of temperature on the gelation time of M1-2.5GP formulation. 
Temperature (°C) Gelation time (min) 
29 49.6 ± 3.4 
31 16.5 ± 1.9 
33 9.3 ± 1.6 
35 6.3 ± 0.6 
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The formulation underwent sol-gel transition in a time shorter than the half life of the mucociliary 
clearance at all temperatures above 29 °C. The polyol, GP, provides protective hydration of TMC, 
maintaining the polymer chains stretched in solution, as the inter- and intra-molecular crosslinking 
within the system is reduced [4]. Upon raising the temperature to 35°C, the increased kinetic energy 
favours the formation of hydrophobic interactions between chains. The addition of PEG allows the 
formation of an even more extensive gel network by providing extra sites for hydrogen bonding [4].  
Gelation was accompanied by a significant change in viscoelasticity, G* (Fig. 6a). Apparent viscosity 
increased with increasing temperature; this increase was not statistically significant for formulation 
H2 (5 % w/v GP), (Fig. 6b). The effect of temperature was most pronounced for formulation M1 (2.5 
% w/v GP), which displayed the most significant differences, p < 0.0001, in both viscosity and 
viscoelasticity. Hydrogel H1 (2.5 % w/v GP) exhibited the lowest gelation temperature and the 
fastest gelation time (19.6 ± 0.6 °C, 13 ± 4 s), since the long polymer chains formed extensive 
hydrophobic interactions. Formulation H2 (5 % w/v GP) did not show significant thermoresponsive 
behaviour with respect to the apparent viscosity (Fig. 6b); the higher degree of quaternisation 
increased solubility and enhanced electrical repulsion between TMC chains to prevent a substantial 
change in viscosity. These data are in agreement with the literature, demonstrating that the 
components concentration and polymer characteristics all have an effect over the gelation time and 
temperature of the formulation [216-218]. 
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Figure 6. (a) Complex modulus (G*) and (b) apparent viscosity values for TMC/PEG/GP hydrogel formulations at 15 ⁰C (white) and at 35 ⁰C (black). 
Results are given as mean ± SD (n=4): ***p<0.001, **p<0.01, *p<0.05; Tukey-Kramer post-hoc comparison test.
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 Rheological properties of the hydrogels 
 
Fig. 7 summarises G* and η data – the rheological properties of polymer–mucus mixtures that have a 
most significant impact on MTR [206] – for hydrogel-mucin mixtures at 15 and at 35 °C. The very 
significant (p < 0.001) increase in G* seen for M1 and for H1 is consistent with mixtures that are 
capable of exhibiting prolonged residence in the nasal cavity [206]. The complex modulus (G*), 
which describes the rigidity and overall strength of the gel, is used as a parameter to monitor the 
effect on MTR. Gels of increasing G* were found to increasingly reduce MTR, due to the inability of 
the cilia to penetrate effectively into the gel (elastic properties), decreasing the efficiency of energy 
transfer to the mucus/polymer layer (viscous properties) [206].  
 
Figure 7. (a) Complex modulus (G*) and (b) apparent viscosity, at 15 ⁰C (white) and 35 ⁰C (black) of 
TMC/PEG/GP hydrogel-mucin mixtures. All formulations were prepared with 2.5% GP. Values are 
given as mean ± SD (n=4). Data above the red line indicate (a) G* values required to decrease MTR 
by at least 80% and (b) ɳ values required to decrease MTR by at least 60% [206]: ###p < 0.001, 
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comparing 15 ⁰C to 35 ⁰C, ***p < 0.001 with respect to water; Tukey-Kramer post-hoc comparison 
test. 
 
At 35 °C, the same hydrogel–mucin mixtures displayed apparent viscosity values > 350 mPa s, but at 
15 °C only M1 mixtures had viscosities < 350 mPa s; identifying M1 as the material of choice for the 
formulation of thermosensitive nasal sprays or drops. Hydrogels L1 and L2 appeared to be of little 
value to nasal delivery since their rheological properties were not significantly different to those of 
water (p > 0.05), at either temperature. Similarly, hydrogels M2 and H2 did not meet the 
requirements (G* > 200 Pa; η > 350 mPa s) for use as thermosensitive nasal-delivery systems [206].  
 
 Hydrogels–mucin interactions 
 
Oscillation profiles of L1, M1, and H1 and of their mixtures with mucin are presented in Fig. 8, along 
with those of mucin alone.  
 
Figure 8. Dynamic oscillation spectra of TMC/PEG/GP hydrogels (all hydrogels containing 2.5 % GP) 
and of their mixtures with mucin at 35 ⁰C: (a) L1; (b) M1; and, (c) H1 – G’ hydrogel–mucin ( ); G” 
hydrogel–mucin (  ); G’ hydrogel ( ); G” hydrogel ( ); G’ mucin (  ), G” mucin ( ). 
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The storage and loss moduli of mucin show some frequency dependency, with a cross-over at ca. 2 
Hz, as is typical of the behaviour of weakly entangled polymeric systems [219]. The observed 
behaviour of mucin is different to that of physiological mucus, for which G’ > G” over the entire 
frequency range [42]. The oscillation spectra of M1–mucin mixtures (Fig. 8b) show that G’ > G” over 
the entire frequency range, which is consistent with the behaviour of a strongly cross-linked gel [42], 
consequently indicating that there is substantial interaction between the hydrogel and the mucin. By 
contrast, L1-mucin mixtures (Fig. 8a) behave as a physically entangled system, exhibiting G” > G’ over 
a broad spectral range along with a substantial decline in G’, and to a lesser extent G”, at low 
frequencies [42], therefore showing a lower degree of interaction between the two systems upon 
mixing. The oscillation spectra of the H1-mucin mixture, Fig. 8c, show a predominance of elastic 
behaviour (G’ > G”) with some degree of physical entanglement (G” > G’) at lower frequencies. The 
mixing of H1 with mucin results in a more pronounced increase in G” than in G’, which is interpreted 
as an increase in the fluidity of the system since there is a low degree of entanglement between the 
longer coiled TMC chains and mucin, decreasing mucoadhesive potential. Comparison of the 
rheology profiles of L2, M2 and H2 with those of their mixtures with mucin reveals no significant 
differences in dynamic moduli. For these materials the increase in aqueous solubility following the 
quaternisation of TMC is accompanied by a predominance of viscous properties and a suppression of 
the elasticity of the hydrogel. Since all materials share the chemical features of chitosan, their 
capacity to enter into rheologically synergistic relationship with mucin must be a direct consequence 
of the combined effects of their average molecular weight and degree of quaternisation [53, 220-
222].  
The addition of mucin to the H1 hydrogel, Fig. 9, effects an increase in G’, indicative of the 
homogeneity of the mixture, and a more pronounced increase in G”, which shows that mucin/H1 
mixtures are less elastic and more viscous than the parent hydrogel. The relative G’ of the mucin/M1 
mix, Fig. 9, is consistent with the high compatibility of the constituent materials in their forming of 
homogeneous mixtures.  
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Figure 9. The synergistic effect of TMC/PEG/GP hydrogels-mucin mixtures evaluated using relative 
G' and G" values at 35 ⁰C. 
 
2.4.3. Mucoadhesive behaviour 
 
As is prerequisite to good mucoadhesive behaviour, all hydrogels displayed their capacity to hydrate 
readily and hold high quantities of water (Fig. 10a) [12, 48, 131, 133, 222, 223]. The water-holding 
capacities of the low degree of quaternisation hydrogels M1 and H1 are comparable with those of 
poly(acrylic acid), the archetypal mucoadhesive polymer. Complementary work-of-adhesion 
measurements identify M1 as the hydrogel of choice for employment in mucoadhesive formulations: 
M1 is the only material that yielded work-of-adhesion values (735 ± 98 µJ) that are comparable with 
those of poly(acrylic acid) (p > 0.05). The work-of-adhesion values determined for hydrogels L1, L2, 
M2 and H2 were similar (p > 0.05) to that obtained for tristearin, the negative control (Fig. 10b). The 
results correlate with those from rheological investigations, and highlight the complementarity of 
the techniques in the evaluation of the mucoadhesive potential of a material. 
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Figure 10. (a) Water holding capacity (WHC; mean ± SD, n = 5) of hydrogel formulations in SNES-mucin solutions: **p < 0.001, ***p < 0.0001 with 
reference to M1; Tukey-Kramer post-hoc comparison test. (b) Total work of adhesion (TWA; mean ± SD, n = 5) of TMC hydrogels, poly(acrylic acid) 
(positive control) and tristearin (negative control): ***p < 0.001 and *p < 0.05 with respect to the positive control; Tukey-Kramer post-hoc comparison 
test
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2.4.4. Physicochemical characterisation of hydrogels 
 
As exemplified by infrared spectroscopy of H1 (Fig. 11), hydrogels exhibit the vibrational features of 
all constituents of the formulation: features associated with PEG are evident at the aliphatic C-H 
stretch region (ca. 2700 cm-1) and also in the skeletal fingerprint region, whereas TMC manifests 
itself in the hydrogen bonded region (> 3000 cm-1). In H1, the broad absorption arising from 
hydrogen bonded interactions  due to the –NH and –OH functionalities of the TMC constituent of the 
hydrogel are shifted to higher frequencies relative to those of pure TMC. This shift is consistent with 
the predominance of intermolecular hydrogen bonding over corresponding intramolecular 
interactions [224] and confirms the homogeneous nature of the formulation.  
 
Figure 11. IR spectra of TMC H1 (blue) and TMC(H1)/PEG/GP hydrogel (red). 
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Figure 12. (a) SEM micrographs, (b) surface area (SBET), and (c) total pore volume (VP) of 
TMC/PEG/GP hydrogel formulations (2.5 % GP). (a)  
Surface area analysis, Fig. 12, shows that in a direct relationship with the average molecular weight 
of each material, SBET (Fig.12b) adopts values that are as low as 0.08 m
2g-1 or as high as 4.88 m2g-1. 
This trend corresponds with SEM images of pore size, Fig. 10a, and with determinations of pore 
volume, Fig. 12c: hydrogels that had been dried for SEM imaging exhibited pore diameters varying 
from ca. 4 nm to 1 μm. As expected [225], trends in porosity and SBET data follow those for water 
holding capacity; hydrogels that hold more water present higher porosity values. With the exception 
of H1, the mucoadhesive behaviour of the materials also correlated well with trends in internal 
surface area and porosity. Furthermore, porosity data can help predict the diffusion of drug 
molecules within the gel [43, 85, 93]. 
 
2.5. Conclusion 
 
Co-formulation of poly(ethylene glycol) and glycerophosphate with N-trimethyl chitosan of medium 
average molecular weight and low degree of quaternisation yields  an aqueous formulation that 
exhibits a sol-gel transition at 32.5 °C and within 8 min. The same hydrogel forms rheologically 
synergistic mixtures with mucus and also exhibits good affinity for mucosal surfaces. The properties 
of this hydrogel appear to be consistent with its potential use as an in-situ thermogelling drug-carrier 
system for intranasal drug delivery. Further studies are underway to investigate its absorption 
Chapter Two 
 
61 
 
enhancing properties and biocompatibility. Positive preliminary results indicate this is a promising 
formulation. 
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A thermosensitive, mucoadhesive intranasal hydrogel 
based on N-trimethyl chitosan: structural integrity, in 
vitro insulin release, cytotoxicity and transport across 
Calu-3 monolayers. 
 
Abstract 
 
An in situ thermogelling, mucoadhesive formulation based on N-trimethyl chitosan chloride has been 
evaluated for its potential to affect the transmucosal delivery of insulin via the nasal cavity. 
Spectroscopic and analytical investigations (UV-vis, fluorescence, IR, Raman and SDS-PAGE) have 
indicated that the incorporated insulin is in monomeric form and that it retains its structural 
integrity and conformational order over several days.  In vitro studies at a physiologically relevant 
temperature (35 C) have shown that the formulation releases most of its insulin load (ca. 70%) in a 
non-Fickian manner during the timescale over which the gel-to-sol transition (ca. 8 min) takes place, 
but once gelation is complete the release of the remainder of the therapeutic content follows first 
order kinetics over at least sixty minutes. Investigations on the effects of the same formulation on a 
model nasal mucosa (Calu-3 cell monolayer) have shown the capability of the formulation to effect 
the transient opening of tight junctions.  
 
3.1. Introduction 
 
The impetus for research into transmucosal drug delivery of peptides and proteins is provided by the 
invasiveness of the parenteral alternative [1]. Consequent to the generally unfavourable transport of 
macromolecules through mucosal membranes, approaches for enhanced absorption have included: 
co-administration with protease inhibitors [226]; inclusion of permeation enhancers [227]; 
modifications of peptide structures to improve metabolic stability or membrane permeation [3]; 
and, the development of mucoadhesive systems that prolong residence time upon the absorptive 
surface [228].  
Owing to its accessibility, large surface area and thin epithelium, the nasal mucosa may prove useful 
for the possible delivery of therapeutic macromolecules that cannot withstand the challenges of the 
gastrointestinal tract. To this end, research efforts have examined the potential use of several types 
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of formulation, including powders [229], microspheres [230], nanoparticles [231], solutions [232] 
and gels [4].  The supporting matrix of such formulations is often derived from chitosan, a 
mucoadhesive polysaccharide that is known to enhance the permeability of the nasal membrane by 
promoting the transient opening of tight junctions [4, 229, 231, 232].  
Towards the in vitro testing of such formulations, cultured nasal epithelium provides a useful model 
for the study of nasal drug absorption in that it allows a preliminary assessment of the permeability, 
toxicity, metabolism and transport of potential therapeutic agents [233]. A useful surrogate for 
human nasal epithelia is provided by Calu-3 cells [234, 235] – these are a well characterised, human 
respiratory tract epithelial cells that can be cultured as confluent monolayers at the air-medium 
interface [236, 237]. 
In previous work [146], we have reported the preparation and characterisation of an in situ 
thermogelling formulation based on N-trimethyl chitosan chloride (TMC). The formulation, which 
has been designed for application as intranasal solution, forms a mucoadhesive gel within the 
timeframe of mucociliary clearance (MCC) to effect prolonged residence at mucosal surfaces [146]. 
We now extend this work by assessing the capability of these hydrogels to act as controlled-release 
matrixes for albumin or insulin. Also, by recording the formulation-induced changes in transepithelial 
electrical resistance (TEER), we use Calu-3 monolayers as an in vitro probe of the potential 
permeation-enhancing capacity of the applied formulation. In parallel, we assess the cytotoxicity of 
each formulation by monitoring the essential viability of the Calu-3 monolayer substrates. 
 
3.2. Materials 
 
Chitosan (medium viscosity, 400 kDa, DD 84 - 89 %), and poly(ethylene) glycol 4000 (PEG) were 
obtained from Fluka, UK. Glycerophosphate (GP; equimolar mixture of α and β isomers), 
Bichinchonic acid (BCA) protein kit, Dulbecco’s Modified  Eagle Medium (Nutrient Mixture F12, 
Ham’s; DMEM/F12), penicillin (10,000 U/mL) / streptomycin (10 mg/mL), fetal bovine serum, non-
essential amino acids, l-glutamine, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide 
(MTT), Hank’s Balanced Salt Solution (HBBS), insulin from bovine pancreas, and albumin from 
chicken egg white,  were purchased from Sigma-Aldrich Inc., UK.  Methyl iodide and 1-methyl-2-
pyrrolidinone were sourced from Acros Organics, Belgium. Dialysis tubing CO 12 – 14000 Da was 
obtained from Medicell International. Materials used for SDS-PAGE were sourced from Invitrogen 
Ltd, UK: Novex Tricine SDS Buffer kit and  Novex 10-20% Tricine Gel 1.0mm. Human cell line Calu-3 
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was sourced from ATCC-LGC, UK.  All other chemicals were obtained from Fisher Scientific, UK, and 
used as received.  
 
3.3. Methods 
3.3.1. Preparation of thermosensitive and mucoadhesive TMC hydrogel 
 
N-Trimethyl chitosan chloride (degree of quaternisation = 32.8 %) was synthesised from medium 
molecular weight chitosan as previously described [146]. Albumin (ca. 40 kDa) or insulin (ca. 5 kDa), 
both at 3 mg/mL, provided the model molecules for studies of the release of proteins from the 
hydrogel matrix.  
 
The albumin- or insulin-loaded sol-state hydrogels were formed by mixing GP (12.5 % w/v) with a 
solution of insulin or albumin (3 mg/mL) in aqueous HCl (0.1M; 1 mL) and then adding (dropwise, 
stirring) the resulting solution to a pre-prepared solution (4 mL) of TMC (4.5 % w/v) and PEG (6.75 % 
w/v). The pH of the formulation was in the range 4.8- 5.3. The gelation time and temperature, and 
the thermosensitivity and viscoelastic properties of the hydrogel were consistent with those 
reported [146] for corresponding systems prepared in the absence of HCl.  
 
3.3.2. In vitro protein release 
 
Uniformly cut dialysis membrane (volume capacity = 3 mL; molecular weight cut-off 12,000-14,000) 
was used to assess the in vitro release of albumin or of insulin from the hydrogel system; prior to 
filling with each sol-state hydrogel, the artificial membrane was allowed to stand in PBS (pH7.4, 24 
h).  Each dialysis sac was suspended in SNES-release media (SNES: 7.45 mg mL-1 NaCl, 1.29 mg mL-1 
KCl and 0.32 mg mL-1 CaCl2.2H2O; adjusted to pH 5.5 with 1M aqueous HCl) that had been 
thermostatted at 35 °C and stirred (70 rpm). Aliquots (100 µL) for the analysis of albumin or insulin 
content (bichinchoninic acid (BCA) protein assay kit) that had been removed at specified time 
intervals, over 1 h, were replaced immediately with fresh, warm (35 °C) SNES-release media. 
Experiments were performed in quadruplicate. 
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 Drug release kinetic modelling  
 
To assess the possible drug-release mechanism data were fitted to the Korsmeyer-Peppas 
equation[238]: 
Equation 4. Korsmeyer-Peppas equation. 
Mt/M∞ = K t
n                                                                                                                                                                                                                                       (1) 
Where Mt is the amount of drug released at time t; K is the apparent rate constant, which is related 
to the structure and geometry of the dosage form; Mt/M∞ is the fractional release of drug at time t; 
and n is the release exponent, the numerical value of which characterises the mechanism of drug 
release (n < 0.45, Fickian Release; 0.45 < n < 0.89, non-Fickian Mass Transfer; n > 0.89, Case II 
Transport).  
 
3.3.3. Integrity of released protein 
 SDS Page 
 
The integrity of released protein, insulin and albumin, from the 60 min in vitro study was assessed 
means of a 10-20 % SDS-PAGE study. The protein standard and samples of released protein were 
each loaded into individual wells using a micropipette, and the electrophoresis experiment (125 V, 
90 mA, 12.5 W) was performed over 75 min. Protein bands were visualised following staining with 
SimplyBlue SafeStain (1 h, room temperature) and images of dried gels (wiping) were recorded using 
a scanner. 
 
 UV-vis, FTIR and Raman analysis 
 
 UV-Vis spectra of insulin solutions (3 mg/mL) in aqueous HCl (0.1 M) were recorded (230-350 nm) 
using a Unicam UV2 UV-Vis spectrophotometer. To monitor the stability of these solutions, spectra 
were recorded over one week and second derivative spectra were compared by means of the 
Friedman test using PASW® Statistics 18 software. Infrared spectra were recorded using a Varian 
640-IR FTIR (Varian Inc., Palo Alto, USA; 400-4000 cm, absorbance mode, 4 cm resolution, 32 scans). 
Fourier Transform Raman (FT-Raman) spectra were recorded using a Thermo Scientific Nicolet 6700, 
NXR FT-Raman module, CaF2 beam-splitter, coupled to Omnic 8.0 software. Raman excitation was by 
means of a A R510 diode pumped Nd:YAG laser operating at 1064 nm; optical filtering reduced the 
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Rayleigh elastic scattering and, in combination with a CaF2 beamsplitter and a high sensitivity liquid 
N2-cooled Ge-detector, allowed the Raman intensities to be recorded over the range 50-3300 cm in 
the Stokes side.  
 
3.3.4. Calu-3 cell culture 
 
The differentiated human, mucus-producing, submucosal gland lung carcinoma cell line, Calu-3,  
were cultivated in flasks (80 cm3) a using Dulbecco’s Modified Eagle’s Medium (DMEM)/F12 Ham’s 
50:50 supplemented with  non-essential amino acids (1% w/v), fetal bovine serum (10% w/v) and 
penicillin and streptomycin (50 µg mL-1) or 0.005% w/v. Cells were maintained in a controlled 
atmosphere (95 % air, 5 % CO2) at 37 ˚C. The culture medium was changed every two days until cells 
were at 80 – 90 % of confluency (ca. 7-10 days). After the passage process, cells were seeded at 2 × 
106 cells per flask. 
 
 Measurement of transepithelial electrical resistance  
 
Transepithelial electrical resistance (TEER) of monolayers of cells, seeded at a density of 4 x 105 Calu-
3 cells cm-2, was measured using Transwell© plates fitted with a microporous (0.4 µm) membrane. 
Epithelial monolayer confluence, assessed by inspection under the optical microscope, was complete 
at ca.14 days from seeding; growth medium, 1 mL each at the apical and basal chambers of 
Transwell© inserts, was replenished daily. TEER was monitored using a pair of chopstick electrodes 
(Millipore, Spain) connected to a MIllicel©-ERS instrument. The baseline resistance was determined 
from measurements taken at 60 min prior to the replacement of the growth medium with a mixture 
of the test formulation (hydrogel, or TMC control at 3.6% w/v) and fresh medium. TEER 
measurements were taken at 15 min intervals over 2 h, after which time the sample in the apical 
chamber was replaced with fresh medium, and then for a further 2 h to assess recovery following 
the removal of the test formulation. 
 
 Transport of the active 
 
Transwell© inserts containing cell monolayers at confluence were equilibrated with medium (1 mL in 
each chamber) for 15 min. The medium was then discarded and the inserts were transferred into 12-
well plates containing HBSS (pH 7.4; 1.5 mL) that had been supplemented with glucose (15 mM per 
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well; basal chamber). The monolayers were incubated (37 °C, 10 min) in drug-free transport 
medium.  The test hydrogel (500 µL; pH 4.8- 5.3), or TMC solution (500 µL, 3.6% w/v; pH 4-4.5) each 
containing albumin or insulin (3 mg/mL), was added to the apical chamber and cells were incubated 
at 37 ˚C. Aliquots (100 µL) sampled from the basal chamber, at specified time intervals over 2 hr, 
were replenished with fresh medium. Albumin or insulin transport was evaluated by means of the 
BCA assay. 
 
 Cytotoxicity study  
 
The cytotoxicity of hydrogel formulations and of TMC, PEG and GP solutions in concentrations 
corresponding to those within the hydrogel formulations was evaluated by means of a 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay on Calu-3 cells that had been 
seeded at a density of 104 cells per well into a 96-well plate and incubated in the culture medium for 
2 days.  Following removal of the culture medium, cells were exposed to the test solution (500 µL) 
and incubated for 2 hours at 37 °C; SDS (10 mg/mL) provided the positive control whereas culture 
medium acted as reference for 100 % cell viability. Subsequent to the removal of the mixture of 
medium and test solution, cells were washed with PBS, and a freshly prepared solution of MTT in 
DMEM/F12 (200 µL, 0.5 mg/mL) was added prior to incubation at 37 ˚C for 1 h. After this time, MTT 
solutions were removed from the wells and DMSO (400 µL) was added to facilitate the dissolution of 
the formazan crystals that had formed. Following 10 min of continuous agitation, the absorbance 
was read at 570 nm. 
 
 Confocal Light Scanning Microscopy (CLSM) 
 
The Transwell© inserts used for the transport studies were also used for CLSM visualisation. 
Following the transport study, the monolayers were rinsed apically and basolaterally with sterile 
PBS, and a solution of propidium iodide (30 µg/mL, in DMEM/F12) was applied apically for 3 min. 
The solution was then removed, and the support filter cut from the plastic insert and placed 
between two glass coverslips. The cells were visualised using a Zeiss LSM 510 Meta (Germany) 
instrument, with propidium iodide excitation at 514 nm. Cells that had been free from dye were 
decreed viable; an image of damaged cells (incubated with 0.1 % SDS for 2 h) was used as viability 
comparator. All experiments were carried out in triplicate. 
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3.3.5. Statistical Analysis 
 
The statistical significance of the differences between the viability of Calu-3 monolayers that had 
been exposed to the hydrogel or to its components, as compared with the negative control 
(medium; 100 % cell viability) was tested at the p < 0.05 level by one-way analysis of variance 
(ANOVA) and further by the multiple comparison Tukey-Kramer test.  
Statistical significance of differences between protein transport released from solutions and 
hydrogel systems across Calu 3 monolayers and between TEER values was tested via the Friedman 
test followed by a Wilcoxon Signed Rank post hoc test using PASW ® Statistics 18 software. 
 
3.4. Results and Discussion 
 
Consistent with the performance requirements for efficient drug delivery through the nose, the 
thermosensitive semi-rigid gel formulation has been designed such that it gels at ca. 33°C (the 
temperature of the nasal cavity [32]) and within the MCC timescale (ca. 8 min from administration 
[146]) to exhibit rheologically synergistic interactions with nasal mucus, which in turn effect 
prolonged residence.  
 
3.4.1. In vitro release kinetics  
 
The effectiveness of the thermosensitive hydrogel as a drug delivery device appropriate for its 
proposed use has been assessed by considering the release profiles of incorporated albumin or 
insulin [85].  
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Figure 13. Cumulative release of insulin (      ) and albumin (       ) both at concentrations 3mg/mL 
from TMC/PEG/GP hydrogels. Results are given as mean ± SD (n = 4). 
It appears, Fig. 13, that as the hydrogel system moves from the sol to the gel state it fails to entrap 
all available insulin: the cumulative accumulation of insulin detected in the dialysis medium over the 
first 12 min of the experiment is ca.70 % of that added to the formulation, which, considering the 
time factor associated with the movement of insulin across the dialysis membrane, appears to 
correspond with the time that is required to effect gelation at 35 C (ca.8 min). Consistent with the 
assumption that there is a ca.4 min time lag in the movement of insulin through the dialysis 
membrane, the insulin-release curve in Fig. 13 is characterised by three distinct regions: an initial 
slow release over the first 4 min of the experiment; a rapid release region over the next 8 min; and, 
another stage of slow release between 12 and 60 min. It is at this final stage that the release of 
insulin is assumed to be governed by the gel-state hydrogel. The release profile of albumin also 
exhibits three distinct regions that are demarcated by the same time points. However, since the 
total accumulative release of this agent over 60 min is only ca.5 % of the available material (with 
most of that release occurring in the first 12 min), the hydrogel formulation appears to be of little 
therapeutic relevance as a device for the controlled release of albumin.  Consistent with super case II 
transport (drug diffuses out of the swollen system via a mechanism that  is determined by the 
interaction between the polymeric system and the release medium [239]), the data over the time 
period for the transition from sol to gel (2-12 min; Fig. 13) fit the Korsmeyer-Peppas equation at 
respective n values for insulin and albumin of 1.91 and 1.49. By contrast, the segment of the plot 
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demarcated by the 12 min and 60 min timepoints is characterised by n values of 0.15 (insulin) and 
0.17 (albumin), confirming that the release of the protein content of the gel-state system obeys 
Fickian release [240]. 
 
In view of the effect of the porosity of the hydrogel on the rate of diffusion [85, 93, 241, 242] a 
combination of SEM imaging experiments and BET porosity determinations have been employed to 
examine the shape, size and distribution of the pores: the hydrogel exhibits pore sizes in the range 4 
nm to 100 nm [146], as is typical of such systems  [85]. Since respective hydrodynamic radii for 
insulin and albumin are 1.3 nm and 6.2 nm respectively, the pore size of the hydrogel is not expected 
to be a significant rate-limiting factor in the diffusion of the insulin but is assumed to play a 
significant role in the release of albumin.  
 
3.4.2. Protein structural integrity 
 
Insulin is a protein made up of two peptide chains, A (21 amino acid residues) and B (30 residues) 
which are linked by two disulphide bonds joining cysteine residues A7 and B7 and residues A20 and 
B19 [243]. Galpin et al. [244] have reported that it is the A20/B19 disulphide linkage, which is known 
to be stable under acidic conditions [31], that is crucial for the maintenance of the biological activity 
of the molecule. Also, many structure-activity studies have shown that the preservation of certain 
invariant residues on the surface of the insulin molecule is paramount to the maintenance of its 
receptor-binding activity. These residues include, but may not be limited to: A1 glycine (Gly1); A4 
glutamic acid (Glu4); A5 glutamine (Gln5); A19 tyrosine (Tyr19); A21 asparagine (Asn21); B12 valine 
(Val12); B16 tyrosine (Tyr16); B22 arginine (Arg22); B23 glycine (Gly23); B24 phenylalanine (Phe24) and 
B26 tyrosine (Tyr26) [244]. 
 
Brange et al. [245] have explored the influence of some excipients, formulation environments and 
pH on insulin stability, reporting that at acidic pH, the amino acid Asn21, the C-terminal residue of the 
A-chain, is particularly labile to hydrolytic action. The same workers suggested that the uncharged 
carboxyl moiety at the C-terminal effects the deamidation at A21 via a proton transfer to the amide 
group and a subsequent nucleophilic attack by the thus generated carboxylate ion [245].  Since the 
rate of deamidation is dependent upon pH and temperature, the normal formulation practice is to 
adopt experimental protocols that impact minimally upon degradation, such that the impact upon 
the therapeutic effect is also minimal. In addition, the maintenance of the stereochemistry of the 
molecule is of importance, as is exemplified by the work of Elkordy et al. [246] who have assessed 
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the effects of a peptide’s secondary structure upon biological activity.  Despite this potential 
disruption to the structural integrity of the insulin molecule, the acidic dissolution of insulin during 
aqueous formulation is common practice amongst researchers working towards the development of 
intranasal dosage forms for the treatment of diabetes, Table 12. 
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Table 12. Examples of in vivo and in vitro studies investigating drug delivery systems containing insulin. 
Nature of formulation In vitro studies In vivo studies Reference 
Porcine insulin was dissolved into a solution of 
chitosan in aqueous hydrochloric acid, pH 4. 
Rabbit nasal mucosa 
employed in permeation 
studies using Valia-Chien 
diffusion chambers. 
Intranasal administration of the insulin/chitosan solutions, 10 IU/kg 
insulin, to male Sprague Dawley rats: increasing the concentration of 
chitosan increased glucose-lowering capacity. Solutions of 1.5 % 
chitosan lowered serum glucose levels to ca. 20 % of initial value, 
which was in contrast to the effect induced by the subcutaneous 
control (ca. 40 % reduction).  
[247] 
Bovine insulin was dissolved in 0.1 M HCl and 
adjusted to pH 4.5 with NaOH before adding to gels 
of Poloxamer (P), Poloxamer-chitosan (P-CS) or 
Poloxamer-chitosan/glutaraldehyde/glycine (P-
CS/GA/GY). 
Drug release was determined 
via diffusion through a 
dialysis membrane and tested 
using the Bradford method. 
Intranasal administration to male Wistar rats of polymeric gels 
containing 10 IU/kg insulin: Blood glucose levels decreased to ca. 45, 
48 and 55 % in rats respectively administered with P, P-CS, and P-
CS/GA/GY formulations, as compared with a ca. 35 % reduction 
achieved with the sc control. 
[248] 
A thermosensitive hydrogel was formed by adding 
sequentially recombinant human insulin and α,β-
Glycerophosphate.to a solution of N-[(2-hydroxy-3-
trimethylammonium)propyl] chitosan chloride (HTCC) 
and poly(ethylene glycol) in 0.1 M lactic acid.  
Drug release was monitored 
by the Bradford method.  
Intranasal administration of the thermosensitive HTCC-PEG gel, 10 
IU/kg insulin, to male Sprague Dawley rats effected a ca. 40 % 
reduction to blood glucose after 4 hours from administration. A sc 
control effected the same percentage reduction after 1 hour from 
administration. 
[4] 
A nanoparticulate dosage form was prepared by 
adding a solution of porcine insulin in aqueous 
tripolyphosphate to a pre-prepared solution of PEG-
grafted chitosan in acetic acid. 
Drug release was monitored 
by the Bradford method using 
supernatant collected from 
nanoparticles incubated in 
aqueous media. 
Intranasal administration of  insulin-PEG-g-chitosan suspension and 
insulin-PEG-g-chitosan nanoparticles, both at 5 IU/kg insulin, to 
female New Zealand rabbits lowered respective blood glucose levels 
to 68 % and 54 % of the basal level; a control intranasal insulin 
solution effected a <20 % decrease. 
 
[249] 
Solutions (pH 4).of semi-synthetic human sodium 
insulin mixed with each of a range of chitosan salts 
were prepared by dissolving in aqueous saline. 
 Intranasal administration, 4 IU/kg insulin, to male Wistar rats effected 
variable baseline reductions to blood glucose levels over the range of 
ca. 50 % to ca. 26 %, depending on the nature of the chitosan salt.  
[250] 
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Owing to the complexity of the insulin molecule, the assessment of the effects of the formulation 
strategy upon the molecular structure demands not only the application of a combination of 
spectroscopic investigations  and analytical techniques [246, 251, 252] but also of evaluations of 
biological activity. 
 
 
Figure 14. SimplyBlue SafeStain SDS-PAGE gel of (a) insulin and (b) albumin. Lanes I, II, III and IV 
are respectively: the protein solution; the molecular weight markers; protein loaded into the 
hydrogel, and the protein in the release medium after 60 min. 
 
The application of sodium dodecyl sulfate polyacrylamide gel electrophoresis SDS PAGE has allowed 
the assessment of the effect of 0.1M HCl solution on the chain length of the insulin, Fig. 14a, and of 
the albumin, Fig. 14b, used in this work. The SDS-PAGE results compare the electrophoresis 
behaviour of the loaded protein active within the hydrogel formulation with that of the released 
active after 60 min and that of the commercial protein solution that has been used for loading. The 
molecular weight ladder (Lane II) shows that as expected, the commercial insulin solution (ca. 5 
kDa;Fig. 14a, Lane I) falls between the 4.6 and the 10 kDa markers and the albumin solution (ca. 45 
kDa; Fig. 14b, Lane I) falls between the 40 and 55 kDa marker. The loaded and released actives, 
respectively Lanes III and IV for insulin and albumin, show well-defined bands that correspond with 
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respective bands in Lane I. This matching of bands at ca. 5 kDa and ca. 45 kDa and the absence of 
new bands are both indicative of the preservation of the integrity of the mass and size of insulin and 
albumin, further suggesting that the experimental protocol adopted for the formulation inhibits the 
deamidation at residue 21, at least within the sensitivity limits of the  SDS-PAGE technique [252]. 
Owing to the low amounts of albumin released from the hydrogel formulation, the release of this 
protein was not investigated further.  
 
Figure 15. Fluorescence emission spectra of the native insulin (blue) in 0.02M HCl (aq) and 
released (red) insulin from the peptide hydrogel in SNES (the two solutions are not of equal 
concentrations). 
 
The protonation of insulin following its dissolution in 0.02M aqueous HCl is manifested by a shift in 
the fluorescence emission maximum from 304 nm [253] to 297 nm, Fig. 15. Since tyrosine (4-
hydroxyphenylalanine) is the only amino acid residue present in insulin that is both fluorescent and 
susceptible to protonation by HCl, it is assumed that that the shift in the fluorescence maximum is 
consequent to the reduction in the electron-donating effect of the p-hydroxyl moiety of this residue 
following protonation. The fluorescence emission spectrum of insulin in SNES was slightly broader, 
with evidence for fine structure (with a distinctly weak contribution from phenalanine at 282 nm), 
but exhibited the same absorption maximum (297 nm) as the protonated insulin. The fine structure 
is attributed to differences in the folding of the protein in the two media. 
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Figure 16. (a) UV-vis spectra and (b) Second derivative UV-vis spectra of insulin in 0.02M HCl(aq.) 
solution, monitored over a period of one week: time points: freshly prepared;  at two hours from 
preparation; then at 36, 48, 60, 72, 84 and 96 hours from preparation. The spectra are super-
imposable (chi-square = 0.773 (7); P = 0.998). 
 
Although  insulin in 0.02 M HCl(aq.) solution is in its therapeutically preferred monomeric state [254, 
255], the observed UV absorption maximum (279 nm, Fig. 16(a)) is at a lower wavelength than that 
of monomeric insulin in ethanolic solution (305nm) [256]. Since there is no contribution from 
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aggregation phenomena, this shift is consistent with the reduction in the auxochromic contribution 
of the p-hydroxyl group following the protonation of tyrosine. Monitored over a period of one week, 
the UV-Vis spectra of insulin in 0.02 M HCl(aq.) solution did not exhibit any variations in their 
absorption maxima or in their extinction coefficient (Fig. 16(b)), as would have been expected for 
samples that aggregate or precipitate out of solution. The same set of experiments also confirmed 
the hydrolytic stability of the peptide bonds at the tyrosine and phenylalanine positions, since the 
hydrolysis of those bonds would have been marked by shifts in the positions and intensities of the 
absorption maxima consequent to the liberation of these amino acids or due to their presence as 
terminal groups in insulin fragments.  
 
 
Figure 17. FT-Raman spectra of (a) insulin solid (green); (b) insulin 3 mg/mL in 0.02 M HCl (aq) (red) 
and (c) 0.02 M HCl (aq) (pink). 
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Table 13. Raman assignments of insulin spectral features (from [257]). 
Frequency cm-1 Assignment 
516 v(S – S) 
626 Phe 
646 Tyr 
673 v(C –S) of C – S – S – C   
726 Skeletal bending 
770 Skeletal bending 
834 Tyr 
855 Tyr 
898 v(C – C) 
962 v(C – C) 
1007 Phe 
1035 Phe 
1130 v(C – N) 
1180 Tyr 
1210 Tyr and Phe 
1267 Amide III (α – helical) 
1319 CH deformation 
1341 CH deformation 
1450 CH2 deformation 
1616 Tyr 
1663 Amide I (α – helical structure) 
 
The amounts of insulin released from the hydrogel formulation were sufficiently high to allow the 
acquisition of FT-Raman and FT-IR spectroscopic data (minimum required concentration, 3-5 mg/ml 
[258]). The structural changes that differentiate insulin that had been dissolved in 0.02 M HCl from 
the solid sample, Fig. 17. and Table 13, are manifested by changes in the Raman spectra. Insulin in 
solution is characterised by the disappearance of the insulin bands between 500 and 800 cm-1 and by 
the decrease in the intensities of absorptions between ca. 800 – 950 cm-1 and of those between ca. 
1050 – 1400 cm-1. While the distinct bands that are characteristic of the phenylalanine residue (ca. 
1000 cm-1), the CH2 deformation band (1400 – 1500 cm
-1), and the tyrosine and amide I (α-helical 
structure) (1600 – 1700 cm-1) are evident in both spectra, the loss of some the α-helical structure 
following the dissolution of insulin is suggested by the almost complete disappearance of the amide 
III vibration (N-H bending, 1250-1350 cm-1). The preservation of the amide I stretch (mainly C=O, 
with some contribution from C-N; 1645-1660 cm-1) is consistent with the preservation of some of the 
α-helical structure [246].  
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Figure 18. FTIR spectra of (a) insulin solid, and (b) insulin 3 mg/mL in 0.02M HCl (aq). 
 
Infrared spectroscopic data further support the suggested Raman-evidenced changes in the features 
of the amide III band and are consistent with the preservation of those of the amide I vibrations (in 
aqueous HCl, this band coincides with the 1645 cm-1 bending vibration of water), Fig. 18.  Solid 
bovine insulin displays characteristic absorptions at 1650 cm-1 (amide I); 1540 cm-1 (amide II); 1396 
cm-1, 1452 cm-1 (carboxyl) and 1242 cm-1 (amide III) [259]. While most of these features are 
preserved in the spectra of the acidified solution of insulin, marked differences in the region 1000 – 
1500 cm-1 reflect changes at the structural moiety that is responsible for the amide III (complex 
bands dependent on the details of the force field, the nature of side chains and the extent of 
hydrogen bonding) absorption. Changes in the shape and position of the amide II band, which arises 
from the combined effects of the N-H in-plane bending vibration and the C-N stretching vibration, 
further support the hypothesis that only some of the α-helical structure is lost. The amide A  band 
(mainly N-H stretching vibration, ca. 3500 cm-1) and amide B (about 3100 cm-1), which originate from 
a Fermi resonance between the first overtone of amide II and the N-H stretching vibration, also 
reflect the suggested changes in the structure of insulin, Fig. 18. As is consistent with the presence of 
water, in HCl solution the presence of the amide A band, which does not depend on backbone 
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conformation but is very sensitive to the strength of hydrogen bonding [260] , is only witnessed as a 
shoulder that exhibits the same profile as the amide A absorption. Similarly, the amide B band is 
superimposed on the broad band that is characteristic of the presence of liquid-state water. 
The impact of protonation by aqueous HCl and the associated structural changes imposed upon 
insulin can only be assessed through evaluations of the clinical effectiveness of this molecule. 
 
3.4.5. Cell Culture 
 TEER and protein transport 
 
Tight junction integrity was assessed by monitoring the variations in TEER across the Calu-3 
monolayers following exposure to the hydrogel or to its respective TMC solution. Consistent with 
previous reports [261], both TMC and the hydrogel induced dramatic but transient reductions in 
TEER:  maximal reductions in TEER (respectively 55 % and 43 %, Fig. 19, which were shown to be 
statistically significantly different to one another, p<0.00) were observed at 120 min (the time-point 
at which the applied formulations were removed). 
 
Figure 19. Effect of 3.6 % w/v TMC solution (     ) and TMC/PEG/GP hydrogel (    ) on TEER values of 
Calu-3 monolayers compared to the medium control (    ). Data presented are a mean ± SD (n = 4). 
Dotted line at 120 min is the time point where TMC and TMC/PEG/GP hydrogel samples were 
removed from the monolayers and the following 120 min demarcates the recovery period.  
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 It has been suggested that the capability of TMC to open tight junctions transiently is attributable to 
the disruption of the F-actin cytoskeleton protein through interactions involving the positive charges 
at the C-2 position of the molecular structure [262]. The combination of TMC polymers with 
glycerophosphate is known [232] to reduce the capacity of TMC to open tight junctions, which in 
turn impacts upon the efficiency of absorption enhancement.   
 
Figure 20. Cumulative transport of (a) insulin and (b) albumin (3 mg/ mL)from a 3.6 % w/v TMC 
solution (     ), the TMC/PEG/GP hydrogel   (     ) and from an aqueous protein solution (    ). Results 
are presented as means ± SD (n = 4) and statistical analysis has shown significantly different 
transport between all TMC solutions, their respective hydrogels and the protein solutions. 
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Data for the transport of proteins through Calu-3 cell monolayers treated with hydrogel or TMC 
formulations, or with an aqueous solution of each test protein, Fig. 20, show that TMC has a more 
pronounced penetration-enhancing effect: 7.4% of the available albumin and 72.2 % of the available 
insulin were seen to be transported across the monolayer over 2 h. This, however, may be reflective 
of a TMC-induced decrease in cell viability and/or of the disruption in the confluency of the 
monolayer. Over the same experimental period, the application of the hydrogel formulation effected 
a marked enhancement in the efficiency of protein transport as compared with corresponding 
solutions of each protein (respectively for albumin and insulin: 5 % and 49 % vs. 0.14 % and 73 %).  
 
 Cytotoxicity 
 
Even at short-term (2 h) exposure, the MTT assay unmasked the considerable toxicity associated 
with each of the separate components of the formulation: at concentration levels consistent with 
the hydrogel formulation, respective cell viabilities for TMC, PEG and GP are 40 %, 39 % and 46 %, 
Fig. 21. The observed 60 % reduction in cell viability induced by the 36 mg/mL solution of TMC (32.8 
% DQ) is in marked contrast with reports which suggest that TMC has little or no cytototoxic effect 
[208, 263, 264], and supports the findings of Amidi et al. [234] who showed that a 20 mg/mL 
solution of TMC (25 % DQ) reduces Calu-3 cell viability by approximately 30%. The observation that 
formulations of chitosan exhibit lower cytotoxicity than each of its components (88 % cell viability, 
not significantly different from the medium control; Fig. 21) is in accord with the findings of Kim et 
al. [218], who observed the toxic effects of GP solutions on cancer cells and also demonstrated the 
increased viability of cells treated with a thermosensitive hydrogel that had been formulated from 
chitosan and GP relative to that of cells treated with GP alone. 
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Figure 21. Cytotoxicity assay of TMC/PEG/GP hydrogel and its individual components at the 
corresponding concentrations on Calu-3 monolayers. Results are presented as means ± SD (n = 4). 
* p < 0.001 with respect to medium, 100% viability; Tukey-Kramer post-hoc comparison test. 
 
Towards a further evaluation of cytotoxicity, the hydrogel and each of its components were 
investigated for their effect on Calu-3 cell viability though staining with propidium iodide (a 
membrane-impermeant dye) and subsequent imaging with CLSM. The images confirmed that 
incubation with TMC solution causes considerable damage to the monolayer, as is demonstrated by 
the visualised uptake of propidium iodide by the nuclei of Calu-3 cells, Fig. 22a, but this damage is 
not as pronounced as that caused by SDS (Fig. 22c). The degree of cell-wall disruption in monolayers 
that had been treated with the hydrogel (Fig. 22b) was similar to that of controls that had been 
treated with DMEM/F12 (Fig. 22d). These observations are consistent with the hypothesis that the 
reduction in TEER seen in monolayers that had been treated with the hydrogel was not related to 
cell-membrane damage, as may have been the case for TMC-treated monolayers, and support the 
assertion that the hydrogel promotes the paracellular transport of insulin via the opening of tight 
junctions.  
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Figure 22. CLSM images of Calu-3 cells stained with propidium iodide after 2 hours of treatment 
with (a) 3.6 % w/v TMC solution, (b) TMC/PEG/GP hydrogel, (c) 0.1 % SDS solution and (d) 
DMEM/F12. 
 
3.5. Conclusion 
 
An insulin-loaded, mucoadhesive thermogel formulation based on N-trimethyl chitosan has been 
identified as a candidate vehicle for the nasal delivery of insulin, since in vitro evaluation have shown 
that the formulation combines the capacity  to effect the opening of modelled tight junctions with 
the capability to release its therapeutic content under conditions that mimic those of the nasal 
environment. 
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An in situ thermogelling nasal formulation for the 
intranasal delivery of insulin: in vivo assessment of nasal 
clearance and controlled release profile. 
 
Abstract 
 
The in vivo potential of a readily accessible in situ thermogelling nasal formulation of N-trimethyl 
chitosan chloride, glycerophosphate and poly(ethylene glycol) to act as a once-a-day dosage form 
for the intranasal delivery of insulin has been demonstrated in the rat model. The retention upon 
the absorptive nasal membrane was evaluated to show potentially 60 % of the hydrogel 
formulation still in place after 2 h. The pharmacological activity of the controlled released insulin 
was demonstrated to exert its glucose-lowering effect over ca. 24 hours.   
 
4.1. Introduction 
 
The impetus for the considerable research activities towards the development of an intranasal 
system for the delivery of insulin [17, 230-232, 250, 265-269] is provided by the site-specific 
features of the mucosal epithelium: relatively low barrier to penetration by macromolecular 
actives, low enzymatic activity, avoidance of the first-pass effect, and relative ease of 
administration [5, 30, 137]. The main barrier to the efficient nasal delivery of actives is presented 
by the mucociliary clearance (MCC) [30, 270] – nasal cilia beat in a coordinated fashion to transport 
the mucus to the nasopharynx where it is eliminated by swallowing. Additionally, the absorption of 
macromolecular drugs, such as insulin, is inhibited by the tight junctions that are located between 
epithelial cells [265].  
The main formulation strategy towards the improvement of the residence time of nasal-delivery 
systems involves the use of mucoadhesive agents that disrupt the normal ciliary rhythm, and 
consequently MCC [3]. Zaki et al. have shown [105] that the nasal administration of a poly(acrylic 
acid) mucoadhesive agent (Carbopol 934P) results in the in situ formation of a gel that is capable of 
prolonging the transport time of co-formulated metoclopramide from 10 min (control solution) to 
52 min (mucoadhesive gel) while maintaining mucosal integrity over two weeks of sequential 
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administration. The weak correlation between consistency index (a measure of gel viscosity) and 
MCC (a measure of in vivo mucoadhesiveness) led to the suggestion that the observed 
enhancement in residence time was more likely attributable to the bioadhesive properties of the 
polymer rather than the changes in viscosity induced by the gel [105]. Majithiya et al. [59] have 
suggested that of primary importance in the adhesion of Carbopol to nasal mucosa is the formation 
of hydrogen bonds between the carboxylic acid functionalities of the mucoadhesive and the oxygen 
atoms of oligosaccharide chains at the mucus membrane.  
In vivo work (rat model) by Morimoto et al. [267] using aqueous gels of insulin and poly(acrylic acid) 
(PAA) has demonstrated the glucose-lowering effect of these formulations. The enhancement in 
the nasal absorption of therapeutic agents effected by poly(acrylic acid) has been suggested to be 
due to the combined effects of its mucoadhesiveness, its effects on viscosity and, more 
importantly, on this material forcing the temporary opening of tight junctions as it swells by 
extracting water from the local environment [137]. 
Chitosan, a material that is also capable of effecting the transient opening of tight junctions [271, 
272], has also received considerable interest in the quest for the development of intranasal 
hydrogels for the delivery of insulin [4, 5, 17, 117, 265, 269, 273-278]. Chitosan is known to induce 
the translocation of occludin and of ZO-1 from plasma membranes to cytoplasm, thereby 
facilitating the partial alteration of the cytoskeleton and in turn the opening of tight junctions. Both 
the increasing effectiveness of  chitosan at opening tight junctions and its capacity to establish 
strong mucoadhesive interactions are generally accepted to be enhanced by increases in the 
molecular weight and/or degree of deacetylation [5].  
Chitosan has been combined with poly(vinyl alcohol) to form a thermosensitive in situ gelling 
system for the nasal delivery of insulin, which has been shown to exhibit a prolonged 
hypoglycaemic affect (maximum reduction of blood glucose of ca. 40 % at 4 hours from 
administration) as compared with the subcutaneous insulin control which induced a very similar 
reduction in blood glucose but over a much shorter timescale (1 hour). The potential advantage of 
the chitosan/poly(vinyl alcohol) system over subcutaneous delivery becomes apparent by 
considering the claim that a gradual decrease in blood glucose inhibits the over-hypoglycaemic 
potential of a dosage form [265]. Chung et al. [269] have reported a cross-linked chitosan gel 
(chitosan cross-linked using glutaraldehyde, interpenetrating with Poloxamer and glycine) that 
displays an even more prolonged hypoglycaemic effect (ca. 5 hours).  Work by Yu et al. [232] has 
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shown the concentration-dependent penetration enhancing effects of chitosan in the intranasal 
delivery of insulin [232].   
The enhanced permeability imparted to nasal mucosa by thiolated or quaternised derivatives of 
chitosan, especially N-trimethyl chitosan chloride (TMC), has been shown to be a function of the 
degree of functionalisation [5, 146]. TMC fulfils two further pre-requisites to efficient nasal 
delivery, namely: good mucoadhesive behaviour, and rheological synergy with mucus [146]. 
Accordingly, du Plessis et al. [17] have reported that the nasal co-administration of insulin and 
chitosan in solution effect a twofold increase in the intranasal absorption of insulin, while an 
equivalent solution of  insulin and highly quaternised (60 %) TMC enhances absorption threefold, 
both as compared with a control solution of pure insulin.  
In view of the promise of TMC as a carrier matrix for the intranasal delivery of insulin, we have 
formulated an in situ thermogelling hydrogel, which has been shown by in vitro studies to be 
biocompatible and to exhibit several pre-requisite properties for the intranasal delivery of this 
therapeutic agent, namely: a viscosity profile that is within the MCC-inhibiting range; 
mucoadhesive behaviour that is comparable with that of poly(acrylic acid) (PAA; the archetypal 
mucoadhesive polymer) [146]; and, the capacity to effect the opening of tight junctions.  
We now report the results from studies that have been designed to assess the in vivo (rat model) 
effects of the formulation on MCC and also those of parallel studies designed to monitor the 
hypoglycaemic effect induced as a result of the intranasal release of insulin from the same 
formulation.  
 
4.2. Materials 
 
Orange FluoSpheres© aqueous suspension (1.0 µm; 2 % w/v) was purchased from Invitrogen, 
Paisley UK. Upon dilution, the FluoSpheres© gave a linear fluorescence response up to a 
concentration on 0.02 mg/mL. Streptozocin, sodium pentobarbital, bovine insulin and the glucose 
Trinder kit were obtained from Sigma (St. Louis, MO, USA). 
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4.3. Methods 
4.3.1. Preparation of formulations 
 
N-Trimethyl chitosan chloride (degree of quaternisation, 32.8 %) was synthesised from medium 
molecular weight chitosan as previously described [28].  
The insulin-loaded, sol-state hydrogel (pH 4.8-5.3) was formed by dissolving α,β-glycerophosphate 
(GP) (12.5 % w/v) into a solution of insulin in aqueous HCl (0.1M; 1 mL) and then adding (dropwise, 
stirring) this solution to a pre-prepared aqueous solution of TMC (4 mL, 4.5 %w/v) and PEG (6.75 
%w/v).  
Insulin-loaded TMC solutions (4.5 %w/v; pH 4.0-4.5), insulin solution (0.1M HCl: water in a ratio 1:4, 
pH 4.5-5.0) and TMC solutions (4.5 %w/v; pH 4.0-4.5) were all formulated to a final insulin 
concentration of 250 IU/mL; control hydrogels were formulated with no insulin content.  
 
4.3.2. In vivo studies 
 Nasal clearance studies in rats 
 
Animals were supplied by the Department of Pharmacology of the Beirut Arab University, where 
this series of experiments was conducted. Animal care and handling were performed in accordance 
with the regulations and guidelines stipulated by the Ethical Review Committee at Beirut Arab 
University, Lebanon and endorsed by the ethical committee of the University of Portsmouth, UK. 
Male, Sprague-Dawley rats each weighing 200-300 g were used to measure the in vivo rate of 
mucociliary clearance according to the method of Donovan et al. [79]. Rats were housed in an 
environment of controlled temperature (21 ±  2°C) and humidity (50–70 %). For MCC 
measurements, rats were rendered mildly sedated (by the intraperitoneal injection of sodium 
pentobarbital, 50 mg/kg) before instillation (right nostril) of hydrogel suspension (25 µL) that had 
been loaded with FluoSpheres© (1 % w/v). The FluoSpheres© exiting the nasal cavity were collected 
by swabbing the back of the oral cavity of the rat using moistened foam-tipped applicators. Swabs 
were taken at two minute intervals for the first 30 min and then every 5 min for the following 90 
min. The FluoSpheres© were removed from the applicators by washing (distilled water, 4 mL) and 
the fluorescence of the resulting suspension was determined using a JASCO spectrophotometer FP-
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6200 (excitation 540 nm and emission 560 nm). The mass of FluoSpheres© in the sample was then 
calculated from a previously constructed standard curve.  Controls were provided by a FluoSphere© 
suspension in normal saline (25 µL, 1 % w/v); each experiment was conducted in triplicate. 
The clearance of fluorescent particles in solution and in hydrogel from the nasal cavity is expressed 
as the percentage loss of the total FluoSphere© loaded as a function of time, and as a percentage of 
the total mass recovered at the end of the 120 min experiment period. Since clearance during the 
first 2 min is not controlled by ciliary motility [79], initial clearance rates (k) were obtained from the 
monoexponential fit of data obtained between 2 and 30 min [279]. The time needed for 90 % of 
the total mass recovered from the nasal cavity to clear (t90) was also calculated. Student’s t-test and 
ANOVA were used to determine statistical differences at the p < 0.05 level. 
 
 Induction of diabetes  
 
 Animals were supplied by the Department of Pharmaceutical Sciences of the University of Padua, 
where this series of experiments was conducted. Animal care and handling were performed in 
accordance with the provisions of the European Economic Community Council Directive 86/209 
(recognised and adopted by the Italian Government with the approval decree D.M. No. 230/95-B) 
and the NIH publication No. 85-23, revised 1985. 
Twenty four male Wistar rats, each weighing 200–300 g (pubescent), were housed as pairs in 
plastic cages. The cages were kept in an air-conditioned room (21 ± 2 °C, 50–70 % relative humidity) 
that was maintained at a 12 h light-dark cycle. The animals had free access to basal diet and water 
for one week prior to the induction of diabetes by means of a single intra-peritoneal administration 
of streptozocin (STZ, 45 mg/kg, in 0.9 % aqueous NaCl).  For blood-glucose testing, a few drops of 
blood were extracted from the tail and tested for glucose concentration using the glucose Trinder 
Kit according to manufacturer´s instructions: a rat was considered diabetic if its fasting plasma 
glucose level exceeded 10 mmol/L (or 1.8 mg/mL); only diabetic rats with plasma glucose levels in 
the range 1.8 – 5.0 mg/mL were utilised in further work. 
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 In vivo testing of hypoglycaemic effect of formulations 
 
For the intranasal testing of formulations and controls, diabetic rats were randomly separated into 
6 groups (n=4) for treatment as shown in table 14. 
Table 14. Groups of rats and the dosage forms that were administered. 
Group  Formulation Insulin dose IU/kg 
1 Intranasal hydrogel solution 0 
2 Intranasal hydrogel solution with insulin 10 
3 Intranasal TMC solution  0 
4 Intranasal TMC solution loaded with insulin 10 
5 Intranasal insulin solution 10 
6 Subcutaneous injection (100 % bioavailability) [232]   1  
 
Formulations (10 µL, 2.5 IU; equivalent to 10 IU/kg assuming an average weight of 250 g per 
animal) [232] were administered into the right nostril of each rat (not anaesthetised) using a 
micropipette. Four rats received the sub-cutaneous injection (1 IU/kg). Blood samples (4 drops, ca. 
100 µL) were collected in heparinised tubes prior to administration and then at specified intervals 
post dosing: 30, 60, 90, 150, 210, 270, 330, 390 min. During this time rats were caged in pairs in the 
air-conditioned environment described above and were allowed free access to food and water. The 
blood was phase separated by centrifugation (4000 rpm, 5 min) and the serum glucose level was 
determined, after dilution in distilled water (1:10), using the glucose Trinder Kit [280]. This 
experiment was repeated using another 20  freshly induced diabetic rats that were allocated to 
receive formulations as per groups 2, 4, 5 and 6 (table 1) (n=5). The blood samples were collected 
at time intervals:  0, 30, 60, 150, 270, 390, 520, 1320, 1800, 2740 min in the same way as before. 
The minimum blood glucose concentration (Cmin), and time to reach Cmin (Tmin) were noted and the 
area above the serum glucose levels vs time curve (AAC) was calculated using the trapezoidal rule 
in Microsoft Excel, where the limits of integration were the start and end point of experimentation. 
For groups 2, 4, and 5, calculations were determined from the longer experiment of ca. 2 days, 
whereas for groups 1, 3 and 6 were calculated over the ca. 6 h period. The data collected allowed 
the estimation of the pharmacodynamic availability of nasally administered insulin, Fdyn [4, 232, 
281]: 
Equation 5. Pharmacodynamic availability. 
      
             
            
                                                                                                                          (1) 
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Intranasal and subcutaneous administration are respectively denoted by subscripts in and sc. Mean 
values of Cmin, Tmin, AAC and Fdyn with standard deviations (SD) were calculated for each group. 
Student’s t-test and ANOVA were used to determine statistical difference. Differences were 
considered to be significant for values of p < 0.05. 
Statistical significance of differences between the hypoglycaemic effect achieved by the intranasal 
formulations and the subcutaneous injection was tested via the Friedman test followed by a 
Wilcoxon Signed Rank post hoc test using PASW ® Statistics 18 software. 
 
4.4. Results and Discussion 
 
The design of the intranasal in situ thermogelling TMC hydrogel is such that it can be instilled in the 
sol state (drops or spray), and once in the nasal cavity undergo gelation to form a mucoadhesive 
viscous body [146]. To assess the mucoadhesive behaviour of this formulation, MCC was 
determined by monitoring the clearance of fluorescent microspheres (FluoSphere©) that had been 
mixed with the hydrogel and administered intranasally to rats. 
 
Figure 23. The recovery or clearance of 1 % w/v FluoSphere© following the intranasal 
administration of (      ) FluoSphere© suspension and (     ) TMC/PEG/GP hydrogel. Mean ± SD, n=3. 
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 The control experiment (intranasal instillation of an aqueous suspension of FluoSphere©) has 
shown that the microspheres clearing time is consistent with that expected from a normally 
functioning MCC: ca. 90% is cleared within 20 min, Fig. 23; the reported clearance rate for nasal 
mucus in the rat is 15-20 min [30, 270]. The hydrogel exhibited a significant capability to reduce the 
rate of MCC: FluoSphere© clearance following application from the hydrogel formulation was 
significantly slower than that for the control, with only ca. 30 % of the FluoSphere© content been 
cleared over 20 min. This rate of MCC clearance became even slower after 20 min, presumably as a 
consequence of the formulation being in its gel state (at the temperature of the nasal cavity the 
sol-to-gel transition occurs within ca. 8 min [146]): at 120 min following intranasal administration 
ca. 50 % of the administered FluoSphere© content is still in the nasal cavity as is consistent with the 
bioadhesive nature of TMC [131, 146, 203] and the viscous nature of the hydrogel formulation.  
The determination of the hypoglycaemic activity profile of diabetic rats following the intranasal 
delivery of insulin by means of the thermosensitive TMC hydrogel involved comparison with the 
corresponding profile of  subcutaneously injected insulin from a control group (Fdyn of 100 %; 1 
IU/kg). For both test samples and controls, the dosages of insulin administered to the rats were 
consistent with those normally applied for the evaluation of insulin-delivery systems [4, 232, 282]. 
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Figure 24. Serum glucose levels over (a) 6 hour and (b) 2 day period of rats following 
administration of: (     ) insulin hydrogel; (     ) insulin TMC solution; ( X ) insulin solution; ( X ) 
hydrogel; (      ) TMC solution, and (     ) insulin subcutaneous injection. Mean ± SD, n=5. 
The averaged serum glucose profiles are presented in Fig. 24 (a) and (b). As expected, the nasal 
administration of insulin-free formulations failed to effect a reduction to overall serum-glucose 
levels. Nasally administered insulin solution also failed to induce a serum-glucose lowering effect. 
In fact, over the first 60 min, these formulations effected a slight elevation in glucose levels 
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(relative to the basal level), Fig. 24 (a), which are assumed to mark the stress-induced 
physiologically reactive response induced by the handling of the animals. The serum glucose 
concentration in control-group animals (sc injection) reached its lowest values (Cmin = (47.6 ± 7.9) % 
of the basal value, Table 15) at ca. 1 h from insulin administration, after which time it began to 
increase at a near-constant rate until it returned to almost its original value (97.4 %) after ca. 9 h 
(Fig. 24 (b)). The serum glucose profile of animals that had been administered insulin using TMC 
solution exhibited a similar Cmin ((49.6 ± 9.5) %), which was reached 90 min later (ca. 150 min from 
administration) than that of the control. The return to basal levels was slow with levels returning to 
their basal state towards at ca. 24 hours. Hence, it may be claimed that the TMC preparation is a 
promising candidate for further evaluation in the controlled release of nasally administered insulin. 
The hydrogel delivery system also achieved a Cmin ((55.1 ± 3.0) %) that is almost comparable with 
that of the sc injection or the TMC solution since no statistical difference was observed between 
the sc, TMC solution or the hydrogel system, but this minimum was achieved at ca. 270 min 
(respectively 210 min and 120 min later than those seen following the sc injection or the nasal 
administration of the TMC solution). The subsequent increase in serum glucose was observed to 
occur at similar rate to that observed with the TMC solution, returning to basal glucose 
concentration at ca. 24 hours. However, it must be registered that one of the rats that had been 
administered with intranasal TMC solution died at 9 h from administration – while the reasons for 
the death of the animal are not known, this event highlights the need for the further toxicological 
evaluation of the formulation.  
Calculated with reference to the sc injection group, the pharmacodynamic availability (Fdyn) of 
insulin that had been delivered intranasally via hydrogel or in TMC solution was not statistically 
different (respectively (17.1 ± 2.4) % and (16.8 ± 4.1) %), and much higher than that achieved with 
insulin solution (0.1 ± 0.0) %. Since there was no statistically significant variation in age, weight or 
basal serum glucose levels in the diabetic rats employed for this investigation, it is assumed that 
the administered insulin formulations were responsible for the induced hypoglycaemic response 
[269]. 
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Table 15. The pharmacodynamic parameters of insulin administered to diabetic rats (* over 2740 
min and † over 390 min). 
 
The Fdyn value, Table 15, determined for the intranasal administration of insulin into rats using the 
TMC hydrogel is similar to those reported for the administration of insulin using chitosan solution 
(15.4 %) [232], and somewhat superior to those reported for a chitosan gel (9.3–18.0 %) [269], for a 
chitosan/PVA gel (8.8%) [265]  and for a derivatised chitosan (HTCC)-PEG hydrogel (3.2–7.3 % 
dependent upon PEG concentration) [4]. The observed prolonged lowering of glucose levels, 
manifested by the pharmacodynamic availability of insulin from TMC solution and the TMC 
hydrogel formulation, is consistent with earlier observations that have demonstrated the capability 
of TMC to disrupt the integrity of Calu-3 monolayers [261].  
Barichello et al. [282] have shown that the sc administration into healthy rats of insulin in Pluronic 
F127 gels or in gels containing insulin-PGLA nanoparticles effects a prolonged hypoglycaemic effect 
which is analogous to that effected by the TMC hydrogel formulation (Cmin of ca. 40 % at 3 h; serum 
glucose levels at ca. 60 % of basal at 6 h from administration). Dyer et al. [266] have reported that 
insulin-loaded chitosan nanoparticles, exhibit a Cmin of 50–60 % at ca. 2 h and possess a Fdyn of ca. 
37 %, which does not offer any advantage over chitosan intranasal insulin solution (Cmin of ca. 40 % 
after approx. 90 min, and an Fdyn of ca. 48 %). The nanoparticulate format appears to possess 
greater transmucosal penetrative capacity than the TMC hydrogel presented here, but neither 
surpasses the absorption enhancing characteristics of the insulin-TMC intranasal solution. 
However, owing to the relatively low pH (4.0–4.5) inherent to this formulation, its therapeutic 
relevance remains to be tested [17, 262]. 
 
Formulation Tmin 
(min) 
Cmin 
(% initial 
value) 
AAC † 
(% glucose.min) 
AAC * 
(% 
glucose.min) 
Fdyn 
(%) 
Insulin s.c.* 60 47.6 ± 7.9 13252 ± 1261 22059 ± 9303 100.0 ± 
42.1 
Insulin 
hydrogel* 
270 55.1 ± 3.0  11538 ± 2842 37752 ± 5294 17.1 ± 2.4 
Insulin TMC 
solution* 
150 49.6 ± 9.5 15467 ± 3203 37072 ± 10542 16.8 ± 4.1 
Insulin solution† 210 98.3 ± 5.2 141 ± 32  0.1 ± 0.0 
Hydrogel† 330 98.0 ± 6.9 270 ± 57  0.2 ± 0.0 
TMC solution† 150 98.0 ± 6.2 210 ± 48  0.2 ± 0.0 
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4.5. Conclusion 
 
In vivo experiments in the rat model have demonstrated that an in situ thermogelling nasal 
formulation of TMC is capable of residing at the nasal mucosa over time scales that far exceed 
those of mucus turnover. The same formulation has also been shown to be capable of affecting the 
controlled delivery of insulin, as is demonstrated by the observed in vivo reduction in blood glucose 
over ca. 24 hours. The data highlight the potential of the device as a once-a-day dosage form for 
the delivery of insulin through the nasal route. 
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Future Work 
By the very nature of hydrogel systems, and as has been highlighted by the gel format of this sol-gel 
TMC/PEG/GP example, controlled drug release is the kinetic profile to be expected. This concept 
does not marry well with the established belief of nasal systems to have a fast therapeutic action. 
Small, highly potent drug entities may compensate for the sustained release from hydrogel 
networks, whereas larger drugs requiring a substantial concentration to be absorbed so as to exert a 
pharmacological response are potentially not well suited to the hydrogel intranasal administration. 
The system demonstrated here has shown some favourable characteristics for the potential use as a 
vehicle for the delivery of small proteins, such as biocompatibility, mucoadhesivity and a penetration 
enhancing effect. Further optimisation of the formulation through the reformulation to a nanogel 
may improve the uptake of the loaded insulin through additional active transport mechanisms 
across mucosal membranes. The subsequent absorption profile may render the formulation as a 
quicker acting hypoglycaemic system that would adhere more closely to the fast action expected of 
nasal drug delivery systems. In achieving this, the goal to improving the current invasive therapies 
for glucose control may be more successfully met, since a short/intermediate acting insulin spray 
may act as a replacement to the frequent pre-prandial injections that feature commonly in diabetic 
regimens. 
Whilst retaining the formulation in the current thermosensitive format, the development of an on-
demand pulsatile release system that modulates insulin release in response to physiological demand 
through coupling with a glucose sensor is a possibility. This system could be appropriately designed 
as an injectable sol-gel system that forms a gel implant within the body and acts as an artificial 
pancreas; monitoring glucose levels and subsequently releasing insulin appropriate to the glucose 
concentration recorded. This system could be tailored to act as a controlled delivery device replacing 
the need for long acting insulin injections and providing the basal insulin levels required when 
glucose levels are stable and relatively low. The in-built monitoring system registers the increased 
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glucose levels post-prandial triggering a conformational change to the hydrogel implant to allow 
more rapid release of the loaded insulin for a responsive hypoglycaemic effect. 
The further work is therefore two-tiered, with one aspect directed towards the further 
development of the formulation so it is fit for purpose to the nasal mucosal membrane, and 
another that involves diversifying the application of the hydrogel to another administration route. 
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